Introduction {#sec1}
============

Purines are important building blocks used effectively across various disciplines. Functionalization and modification of purines have been of interest for synthetic organic chemistry, medicinal chemistry, and toxicology as reflected by the half-century application and development of purine-based anticancer or antiviral agents.^[@ref1]−[@ref4]^ Purines are also of interest as detection probes^[@ref5]−[@ref9]^ and as mechanistic probes for understanding cellular responses to DNA and RNA modification.^[@ref10],[@ref11]^ Approaching these highly functionalized heterocycles often requires tuning of existing or development of new synthetic routes. Overcoming challenges associated with the reactivity of 3-deazaadenine derivatives, in particular, has been approached through de novo construction of 3-deaza-3-substituted purine backbone or functionalization of nucleosides. Several modifications, such as 3-methyl, the related protected 3-hydroxymethyl, and methylenethiol or nitro groups were reported.^[@ref12]−[@ref15]^ 3-Deaza-3-fluoroadenosines had to be synthesized stepwise, but other 3-halo derivatives could also be obtained through direct halogenation of the nonsubstituted 3-deazaadenosines.^[@ref16]−[@ref22]^ The use of cross-coupling reactions in C3 modification of purines is, however, limited. Examples of palladium-catalyzed methylations of 3-deaza-3-bromoadenosine analogues through Kumada coupling have been demonstrated.^[@ref17],[@ref20]^ Recently, the modification of adenosine nucleosides through Sonogashira cross-coupling has been reported, providing access to 3-deaza-3-alkyne adenosine derivatives.^[@ref8],[@ref9],[@ref23]^ However, the use of nucleosides as substrates for cross-coupling reactions can be challenging due to the presence of potentially labile glycosidic bonds or nucleophilic functional groups that have to be protected to achieve the compatibility with many organometallic reagents, as reflected by the reported examples of Negishi and Kumada reactions for the introduction of alkyl or benzyl substituents.^[@ref24]−[@ref27]^ Given the importance of modified nucleobases itself, the method that would allow a direct access to C-3 modified purine scaffolds would be therefore of interest. Here, we describe a general strategy that allows the deliberate synthesis of various 3-deaza-3-substituted purine analogues through metal-catalyzed cross-coupling reactions.

Results and Discussion {#sec2}
======================

En route to 3-deazaadenine analogues of purines, we first investigated the reactivity of the readily available 3-deazaadenine **1** ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}) in cross-coupling reactions.^[@ref15]^ In direct attempts to utilize it as a cross-coupling partner, we were able to obtain the 3-iodo-3-deazaadenine **2** and observe its acceptable reactivity under Suzuki cross-coupling conditions using the Pd(OAc)~2~/3,3′,3″-phosphanetriyltris(benzenesulfonic acid) trisodium salt (TPPTS) catalyst system, a general method developed for aqueous coupling reactions of halogenated purine/pyrimidine nucleobases and nucleosides.^[@ref4],[@ref26],[@ref28]^ The reactions of **2** with phenylboronic acid and *trans*-2-phenylvinylboronic acid afforded compounds **3a** and **3b** with 65 and 58% yield, respectively ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).

![Synthesis of Compounds **1--4**](ao-2017-01159r_0002){#sch1}

Despite the sufficient results obtained for Suzuki cross-coupling of **2** with model aryl/vinylboronic acids, this condition failed in the attempt to produce an alkyl analogue with model ethylboronic acid, similarly as reported by other authors.^[@ref26]^ The reactivity of **2** can be hampered by its low solubility in organic solvents and the presence of active nucleophilic nitrogens. When the amino group at C6 was protected as an isobutyryl amide (the established purine protecting group), the more soluble *N*-(7-bromo-1*H*-imidazo\[4,5-*c*\]pyridin-4-yl)isobutyramide **4** was obtained ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).^[@ref15]^ Various Suzuki coupling conditions of **4** with phenyl- and isobutylboronic acids were investigated, involving metal catalysts, such as Pd(PPh~3~)~4~, Pd~2~(dba)~3~, PddppfCl~2~, and NiCl~2~(dme); ligands, such as PCy~3~, (*t*-Bu)~2~PMeHBF~4~, and SPhos; and bases, such as K~2~CO~3~, Cs~2~CO~3~, K~3~PO~4~, and KO*t*-Bu in ethereal or alcoholic solvents.^[@ref29]−[@ref33]^ Typically, the unreacted starting material was recovered from the reaction mixtures, highlighting the lack of reactivity of **4**. Also, the liability of amide protecting group prohibited the use of aqueous coupling conditions utilizing bases such as carbonates.

We have also evaluated the possibility of using a commercial C6-chloro (**5**) and the known C6-azide^[@ref34]^ (**5b**) purines as starting materials amenable for further amination and reduction, respectively, to access 3-deazaadenine. However, attempts to install a halide at C3 (compound **6**, [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}) have failed, precluding further evaluation.

As the electron-withdrawing groups at C6 (chloride, amide, or azide) were shutting off the reactivity of C3 position, we hypothesized that the use of electronically more neutral protecting groups will promote the solubility of **1** and retain its reactivity toward cross-coupling reactions. Unfavorably, the direct attempts to react **5** with bisbenzylamines to produce the desired cross-coupling partner of type **13** ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}) failed even under harsh conditions (e.g., 140 °C, neat or dimethylformamide (DMF)/K~2~CO~3~), reflecting the evident low reactivity of this substrate toward direct displacement of chlorine atom.^[@ref12],[@ref34]^ We decided to investigate the catalytic aminations with bis(4-methoxybenzylamine) ((PMB)~2~NH) on **5**. In parallel, the catalytic amination of PMB-protected analogue was investigated, considering the reported challenges for modifications of unprotected imidazoles.^[@ref35]^ It should be noted that PMB protection of **5** (PMBCl, K~2~CO~3~, *N*,*N*-dimethylacetamide (DMA), 45 °C, 24 h, 96% yield) yielded a ∼1.6:1 mixture of N9- and N7-PMB-protected products that was used directly.^[@ref36]^ Several literature conditions applicable for chloroarenes, 6-halopurines, and their nucleosides were investigated.^[@ref37]−[@ref42]^ RuPhos and its Pd-bound precatalyst in the presence of NaO*t*-Bu in tetrahydrofuran (THF)^[@ref41]^ have been shown to be particularly successful for the reactions of nonactivated heretoaryl chlorides with secondary amines. Under these conditions, up to 19% of N9-PMB-protected product (identical to **13-H**, [Experimental Section](#sec4){ref-type="other"}) was obtained, albeit with higher catalyst loading (6 mol %) and prolonged reaction time (43 h). However, a significant decomposition was observed. The use of LiHMDS instead of NaO*t*-Bu led to the exclusive decomposition of both protected and nonprotected **5**. Next, Pd(OAc)~2~ was tested in combination with ligands, such as BINAP, SPhos, and XPhos, in the presence of Cs~2~CO~3~ or NaO*t*-Bu in solvents, such as toluene, THF, dioxane, and DMF.^[@ref37]−[@ref40],[@ref42]^ Significant decomposition was observed in the majority of cases, but no product formation. Some level of success was achieved with the combination of Pd(OAc)~2~ (0.1 equiv) and SPhos (0.2 equiv) in the presence of NaO*t*-Bu in toluene (110 °C, 22 h). **13-H** was isolated in 21% yield, reflecting the low reactivity of heteroaryl chlorides with secondary amines.^[@ref40],[@ref41]^ For practical purposes, we have not investigated this reaction further.

![Synthesis of Compound **13**](ao-2017-01159r_0003){#sch2}

To overcome hurdles posed by the limited reactivity of the tested substrates, we decided to construct the fully protected 3-deazaadenine analogue from the cheap, available precursors, using a similar route as reported in the literature.^[@ref15],[@ref43]^ The highly regioselective sequential substitutions of 4- and 2-chloro atoms of the known derivative **9**([@ref43]) with 4-methoxybenzylamine (PMBNH~2~) followed by (PMB)~2~NH produced compound **11** ([Experimental Section](#sec4){ref-type="other"}), and upon further reduction of the nitro group and cyclization, we were able to obtain the target 3-deazaadenine precursor (**13**) with the exclusive N9-PMB protection and 26% overall yield in six steps from a commercial 3-nitropyridine-2,4-diol **7** ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). The length of the synthetic route is similar to that of **1**([@ref15]) but offers access to the fully protected soluble starting material amenable to functionalization.

Gratifyingly, a variety of different coupling conditions involving **13** were successfully demonstrated, as shown in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, including the examples of reactions such as Suzuki^[@ref43],[@ref44]^ (entries 1--5), Heck^[@ref45]^ (entries 6 and 7), Sonogashira^[@ref8],[@ref23]^ (entry 8), Kumada^[@ref46]^ (entries 9 and 10), Negishi (entries 11--14),^[@ref47]^ and the nickel-catalyzed reductive couplings of alkyl halides recently developed by the Weix group (entry 15).^[@ref48]^

###### Transformation Scope for the Metal-Catalyzed Couplings of **13**

![](ao-2017-01159r_0004){#fx1}

  entry   substrate              cond.[a](#t1fn1){ref-type="table-fn"}   product                          yield (%)
  ------- ---------------------- --------------------------------------- -------------------------------- ------------------------------------
  1       PhB(OH)~2~             A                                       **14a**, R = Ph                  91
  2       PhCH=CH~2~B(OH)~2~     A                                       **14b**, R = (*E*)-styryl        79
  3       Ph(CH~2~)~2~B(OH)~2~   B                                       **14c**, R = (CH~2~)~2~Ph        35
  4       EtB(OH)~2~             B                                       **14d**, R = Et                  31
  5       *i*-BuB(OH)~2~         B                                       **14e**, R = *i*-Bu              29
  6       PhCH=CH~2~             C                                       **14b**, R = (*E*)-styryl        53
  7       CH~2~=CHCO~2~Me        C                                       **14f**, R = (*E*)-acrylate      57[b](#t1fn2){ref-type="table-fn"}
  8       PhC≡CH                 D                                       **14g**, R = C≡CPh               89
  9       Al(Me)~3~              E                                       **14h**, R = Me                  87
  10      BnMgCl                 E                                       **14i**, R = Bn                  45
  11      Ph(CH~2~)~2~ZnX        F                                       **14c**, R = (CH~2~)~2~Ph        77
  12      EtZnX                  F                                       **14d**, R = Et                  76
  13      *i*-BuZnX              F                                       **14e**, R = *i*-Bu              85
  14      *i*-PrZnX              F                                       **14j**, R = *i*-Pr              86[c](#t1fn3){ref-type="table-fn"}
  15      Br(CH~2~)~3~CO~2~Et    G                                       **14k**, R = (CH~2~)~3~CO~2~Et   32[b](#t1fn2){ref-type="table-fn"}

Condition A: Ar or vinylB(OH)~2~ (1.5 equiv), Cs~2~CO~3~ (2 equiv), Pd(PPh~3~)~4~ (0.1 equiv), dioxane/H~2~O (2/1), Ar, 90 °C, 6--16 h; condition B: AlkylB(OH)~2~ (1.1--1.5 equiv), K~2~CO~3~ (3 equiv), Pd(PPh~3~)~4~ (0.1 equiv), dry dioxane, Ar, 90 °C, 72 h; condition C: styrene or methyl acrylate (5 equiv), Et~3~N (7 equiv), PPh~3~ (0.5 equiv), Pd(OAc)~2~ (0.1 equiv), dry CH~3~CN, Ar, 90 °C, 36 h; condition D: phenylacetylene (1.5 equiv), Pd(PPh~3~)~2~Cl~2~ (0.1 equiv), CuI (0.1 equiv), dry DMF/Et~3~N (2/1), Ar, 80 °C, 24 h; condition E: Al(Me)~3~ or BnMgCl solution (3--3.3 equiv), Pd(PPh~3~)~4~ (0.1 equiv), dry THF, Ar, 75 °C, 4 h; condition F: ZnCl~2~ (0.5 M in THF, 5.7 equiv), AlkylMgX solution (X = Br or Cl, 8.6 equiv), Ar, rt, 1 h, then **13** (1 equiv), PddppfCl~2~ (0.1 equiv), Ar, rt, 21--29 h; condition G: Br(CH~2~)~3~CO~2~Et (1.1 equiv), Zn (2 equiv), 4,4′-dimethoxy-2,2′-bipyridine (0.1 equiv), NiI~2~ (0.13 equiv), pyridine (0.1 equiv), NaI (0.25 equiv), dry DMA, Ar, rt, 5 min, then 60 °C, 20 h.

Yield isolated after treatment of the crude mixture with *N*-iodosuccinimide (NIS) and separation of **13-I** (for details, see [Experimental Section](#sec4){ref-type="other"}).

Contains ∼20% of *n*-propyl impurity.

The Suzuki couplings could be accomplished with aromatic, alkenyl, and alkyl boronic acids (entries 1--5). Both electron-rich and electron-deficient alkenes were tolerated under the Heck conditions (entries 6 and 7). Sonogashira coupling with phenylacetylene proceeded with high efficiency (89%, entry 8).

The formation of alkyl derivatives, with the challenging substrates containing β-hydrogens, such as alkylboronic acids or ethyl 4-bromobutyrate, was less efficient (29--35%, entries 3--5 and 15) and accompanied by a significant hydrodebromination reaction, indicating the extent of the undesired β-H elimination. This byproduct (**13-H**) could be subjected to halogenation, for example, by the treatment of crude reaction mixtures with *N*-bromosuccinimide (NBS)/NIS, facilitating a chromatographic separation of the cross-coupled product **14**, while the haloderivative **13/13-I** could be recovered (see [Experimental Section](#sec4){ref-type="other"}). The iodo analogue **13-I** obtained this way offered no selectivity enhancement for alkylations using conditions B or F. Propitiously, simple alkyl derivatives could be obtained with improved yields (45--87%) through Kumada-type couplings with substrates such as trimethylaluminum and benzylmagnesium chloride (entries 9 and 10). Ultimately, modified Negishi conditions allowed the access to a variety of primary alkyl derivatives with notably higher yields than those obtained through Suzuki protocol (entries 11--13 vs 3--5). In the case of challenging isopropyl derivative, we observed up to 20% of the known isopropyl to *n*-propyl isomerization (entry 14).^[@ref49]^ Interestingly, our Negishi protocol provided satisfying and consistent results only when an excess of Grignard reagent against an overstoichiometric amount of zinc chloride was used, which helped to improve the solubility of the intermediate organozinc species. This observation seems to be in accord with the works by the Organ group that unveiled the mechanisms involving organozinc reagents in Negishi cross-couplings.^[@ref50],[@ref51]^

Clearly, the fully protected nucleobase **13** allows the use of a broad scope of coupling conditions with not only the formation of saturated and unsaturated C--C bonds, but also the introduction of functional groups, to access the C3-modified 3-deazaadenine derivatives. These results pinpoint appropriateness of the PMB as a protecting group with suitable electronic and chemical properties that allowed to achieve the desired reactivity of **13** among the other tested 3-deaza-3-haloadenine substrates.

We further aimed to elaborate the products to the protected phosphoramidites to verify their compatibility with producing building blocks for solid-phase DNA synthesis. The route to phosphoramidites is exemplified by the synthesis of compound **20i** ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}). We successfully optimized the procedure for complete deprotection of benzyl derivative **14i** affording modified purine **15i**.^[@ref52]^ The known problem of selectivity for purine glycosylations prompted us to use the tetramethylsuccinimide directing/protecting group, developed by the McLaughlin group,^[@ref53]^ to increase the selectivity toward the desired N9 β-glycosylation. The crude salt **15i** was converted accordingly to the corresponding imide **16i** through the reported two-step procedure using tetramethylsuccinic anhydride (Me~4~SA).^[@ref53]^ The imide **16i** was subjected to glycosylation with 1-(α)-chloro-3,5-di-*O*-(*p*-toluoyl)-2-deoxy-[d]{.smallcaps}-ribose, affording the desired N9 β-nucleoside **17i** in 39% yield. The configuration of nucleoside **17i** was unambiguously confirmed by the nuclear Overhauser enhancement spectroscopy (NOESY) experiment ([Figure S1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01159/suppl_file/ao7b01159_si_001.pdf), Supporting Information). It was then elaborated to the corresponding phosphoramidite **20i** through standard methods ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}). Analogously, two other phosphoramidites **20d** and **20e** were prepared from **14d** and **14e**, ethyl and isobutyl analogues, respectively. All three phosphoramidites were successfully used in solid-phase DNA synthesis, and further studies are in progress. Interestingly, the preparation of the corresponding phosphoramidite **20a** from phenyl derivative **14a** could not be achieved due to the destabilizing effect of the Ph group on the glycosidic bond (see [Experimental Section](#sec4){ref-type="other"}). We have also considered the possibility of the direct functionalization of nucleosides by an attempt to prepare a bromo analogue of **17i** through the halogenation of the reported nonmodified 3-deazaadenine phosphoramidite.^[@ref13]^ However, the reactions with NBS in CH~2~Cl~2~ or DMF were unsuccessful, likely due to the electronegative effect of the tetramethylsuccinimide group.

![Synthesis of Phosphoramidite **20i**](ao-2017-01159r_0005){#sch3}

Additionally, the modified 3-deazaadenines could be readily converted to the corresponding 3-deazahypoxanthines, purine analogues of interest for medicinal chemistry,^[@ref36],[@ref54]^ upon treatment with NaNO~2~ as exemplified by the reaction of crude salt **15c** to produce **21c** in 57% yield based on **14c** ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}).^[@ref55],[@ref56]^ This transformation further demonstrates the potential of our synthetic approach toward C3-modified purine scaffold.

![Synthesis of 3-Deazahypoxanthine **21c**](ao-2017-01159r_0006){#sch4}

Conclusions {#sec3}
===========

This study illustrates the merit of a new fully protected 3-bromo-3-deazaadenine derivative developed by us as a building block for the deliberate synthesis of 3-substituted 3-deazaadenine and adenosine derivatives through metal-catalyzed cross-coupling reactions and selective N9 β-glycosylations. It should be expected that both modified purines and their nucleosides will be of interest for applications related to chemical biology, DNA studies, and medicinal chemistry.

Experimental Section {#sec4}
====================

General Methods {#sec4.1}
---------------

All reagents were used as received unless otherwise stated from Sigma-Aldrich, TCI America, Alfa Aesar, AK Scientific, and Chem-Impex International. 4-Chloro-1*H*-imidazo\[4,5-*c*\]pyridine was obtained from MolBridge. Bis(4-methoxybenzyl)amine and TPPTS were obtained from Ark Pharm. 1-(α)-Chloro-3,5-di-*O*-(*p*-toluoyl)-2-deoxy-[d]{.smallcaps}-ribose was purchased from Berry & Associates. Anhydrous methanol, pyridine, and *N*,*N*-dimethylacetamide (DMA) were obtained from Sigma-Aldrich. *N*,*N*-dimethylformamide (DMF) and 1,4-dioxane were dried and stored over CaH~2~ before use. Dry acetonitrile, dichloromethane, and tetrahydrofuran were dispensed from automated Innovative Technology Pure-Solv 400 Solvent Purification System. Analytical thin-layer chromatography was carried out on commercial SiliCycle SiliaPlate 0.2 mm F254 plates. Preparative silica chromatography was performed using SiliCycle SiliaFlash F60 40--63 μm (230--400 mesh). ^1^H, ^13^C, and ^31^P NMR spectra were recorded at room temperature (rt) with a Varian Unity Inova 400 MHz spectrometer. CDCl~3~, dimethyl sulfoxide (DMSO)-*d*~6~, CD~3~OD, acetone-*d*~6~, and D~2~O were used as solvents and referenced to the corresponding residual solvent peaks (7.26 and 77.16 ppm for CDCl~3~, respectively; 2.50 and 39.52 ppm for DMSO-*d*~6~, respectively; 3.31 and 49.0 ppm for CD~3~OD, respectively; 2.05 and 29.84 ppm for acetone-*d*~6~, respectively; and 4.79 ppm for D~2~O).^[@ref57]^ The following abbreviations are used to indicate the multiplicity: s: singlet; d: doublet; t: triplet; q: quartet; m: multiplet; b: broad signal; app: approximate. The coupling constants are expressed in hertz (Hz). The multiplicity of carbon atoms was determined by DEPT-135 experiment; Cq: quaternary carbon. Mass spectrometry (MS) data (electrospray ionization, ESI) were obtained using a Thermo Finnigan LCQ Advantage Ion-Trap Mass Spectrometer. High-resolution (HR) MS data (ESI) were obtained using a Thermo Fisher Orbitrap Elite Hybrid Ion Trap-Orbitrap Mass Spectrometer in Chemical Advanced Resolution Methods (ChARM) Laboratory at Michigan Technological University.

Synthesis and Characterization Data {#sec4.2}
-----------------------------------

Compounds **1**,^[@ref15]^**4**,^[@ref15],[@ref22]^ and **5b**([@ref34]) were prepared according to the reported procedures.

### 7-Iodo-1*H*-imidazo\[4,5-*c*\]pyridin-4-amine (**2**) {#sec4.2.1}

To a suspension of amine **1** (536 mg, ca. 4 mmol) in dry DMF (8 mL), *N*-iodosuccinimide (NIS) (1.125 g, 5 mmol) was added in one portion. A slightly exothermic reaction occurred, and the resulting dark solution was stirred at room temperature for 24 h. After 24 h, the solution was added dropwise to EtOAc (100 mL) with vigorous stirring, and the resulting solid was filtered and washed with EtOAc. The solid was then suspended in chloroform (50 mL) and vigorously stirred under reflux condenser at 70 °C overnight. After filtration and drying in air, **2** was obtained as a dark brown solid in 27% yield (0.27 g). HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~6~H~4~N~4~I: 260.96373; found: 260.96323. MS (ESI): *m*/*z*, 261.2 for \[M + H\]^+^. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ, 8.49 (s, 1H), 8.44 (bs, 2H), 7.97 (s, 1H) ppm. We were not able to obtain satisfactory ^13^C NMR data in DMSO-*d*~6~.

### 7-Phenyl-1*H*-imidazo\[4,5*-c*\]pyridin-4-amine (**3a**) {#sec4.2.2}

This compound was synthesized according to the reported general procedures.^[@ref4],[@ref26]^ To a vial equipped with septa, a mixture of deionized water and acetonitrile (2:1, 9 mL) was added and bubbled with argon for 10 min. **2** (150 mg, 0.58 mmol), phenylboronic acid (88 mg, 0.72 mmol), palladium(II) acetate (7 mg, 0.029 mmol), TPPTS (41 mg, 0.072 mmol), and anhydrous sodium carbonate (183 mg, 1.7 mmol) were added, and the headspace of the vial was flushed with argon for 1 min. The mixture was vigorously stirred at 100 °C for 7 h. The mixture was then cooled and diluted with ethyl acetate (50 mL) and brine (10 mL). The phases were separated, and the aqueous phase was extracted with additional ethyl acetate (3 × 30 mL). Combined organic extracts were dried with MgSO~4~. After filtration and concentration, the residue was purified by column chromatography on silica gel, eluting with 0--10% MeOH in CH~2~Cl~2~ to obtain **3a** as a yellow solid in 65% yield (79 mg). HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~12~H~11~N~4~: 211.09838; found: 211.09680. MS (ESI): *m*/*z*, 211.3 for \[M + H\]^+^. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ, 8.20 (s, 1H), 7.85 (s, 2H), 7.73 (b, 2H), 7.48--7.44 (m, 2H), 7.34--7.30 (m, 1H), 6.46 (b, 2H) ppm. ^13^C NMR (100 MHz, DMSO-*d*~6~): δ, 141.3, 137.5, 136.1, 128.7, 127.3, 126.5 ppm.

### (*E*)-7-Styryl-1*H*-imidazo\[4,5-*c*\]pyridin-4-amine (**3b**) {#sec4.2.3}

This compound was synthesized in a similar fashion to **3a**. To a vial equipped with septa, a mixture of deionized water and acetonitrile (2:1, 6 mL) was added and bubbled with argon for 10 min. **2** (100 mg, 0.38 mmol), *trans*-2-phenylvinylboronic acid (71 mg, 0.48 mmol), palladium(II) acetate (5 mg, 0.019 mmol), TPPTS (28 mg, 0.048 mmol), and anhydrous sodium carbonate (122 mg, 1.2 mmol) were added, and the headspace of the vial was flushed with argon for 1 min. The mixture was vigorously stirred at 100 °C for 16 h. The mixture was then cooled and diluted with ethyl acetate (40 mL) and brine (10 mL). The phases were separated, and the aqueous phase was extracted with additional ethyl acetate (3 × 20 mL). Combined organic extracts were dried with MgSO~4~. After filtration and concentration, the residue was purified by column chromatography on silica gel, eluting with 0--10% MeOH in CH~2~Cl~2~ to obtain **3b** as a cream solid in 58% yield (52 mg). HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~14~H~13~N~4~: 237.11403; found: 211.11269. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ, 8.28 (s, 1H), 7.89 (s, 1H), 7.58--7.56 (m, 2H), 7.38--7.31 (m, 4H), 7.23--7.20 (m, 1H), 6.52 (b, 2H) ppm. ^13^C NMR (100 MHz, DMSO-*d*~6~): δ, 141.1, 139.7, 138.2, 128.6, 126.8, 125.8, 124.0 ppm.

Synthesis of **13** {#sec4.3}
-------------------

Compounds **8** and **9** were prepared by modification of the reported procedures.^[@ref43]^

### 5-Bromo-3-nitropyridine-2,3-diol (**8**) {#sec4.3.1}

To the suspension of 3-nitropyridine-2,4-diol **7** (10 g, 64.1 mmol) in glacial acetic acid (100 mL), bromine (4.6 mL, 90 mmol) was added in one portion, and the mixture was stirred at 70 °C for 2.5 h. The reaction mixture was then cooled and poured onto 300 mL of crushed ice, stirred vigorously for 30 min, and chilled in the freezer for 1 h. The precipitated solids were filtered on paper, washed with a small volume of ice-cold water several times and then with ethanol (3 × 15 mL), and dried in air. **8** was obtained as a yellow solid in 74% yield (11.2 g). ^1^H NMR (400 MHz, DMSO-*d*~6~): δ, 7.86 (s, 1H) ppm. ^13^C NMR (100 MHz, DMSO-*d*~6~): δ, 159.1, 155.6, 138.6, 128.2, 94.0 ppm.

### 5-Bromo-2,4-dichloro-3-nitropyridine (**9**) {#sec4.3.2}

A suspension of **8** (11.1 g, 47.4 mmol) in POCl~3~ (100 mL) was stirred at 90 °C for 24 h under argon, an excess pressure being released for several times within the first few hours. Then, POCl~3~ was carefully distilled off under vacuum. The oily residue was diluted with Et~2~O (100 mL), cooled on an ice bath, and crushed ice (200 mL) was carefully added (exothermic reaction). The phases were separated, aqueous phase was additionally extracted with Et~2~O (2 × 50 mL), and the combined organics were washed with brine and dried with MgSO~4~. After filtration and concentration, the residue was purified by column chromatography on silica gel, eluting with 0--10% EtOAc in hexanes to obtain **9** as a yellow oil that slowly solidified (9.27 g, 72% yield). ^1^H NMR (400 MHz, CDCl~3~): δ, 8.68 (s, 1H) ppm. ^13^C NMR (100 MHz, CDCl~3~): δ, 152.1, 141.5, 137.8, 121.3 ppm.

### 5-Bromo-2-chloro-*N*-(4-methoxybenzyl)-3-nitropyridin-4-amine (**10**) {#sec4.3.3}

To the solution of **9** (9.25 g, 34.3 mmol) in dry DMF (50 mL) at 0 °C under argon, 4-methoxybenzylamine (4.7 mL, 36 mmol) was added in one portion, followed by dropwise addition of Et~3~N (5.5 mL, 36 mmol) over 5 min. The mixture was allowed to warm up to room temperature and stirred for 24 h. The mixture was then diluted with EtOAc (300 mL), washed with brine (4 × 100 mL), and dried with MgSO~4~. After filtration, the solution was concentrated in vacuo to give a yellow solid that was triturated with hexanes to give **10** as a dark orange solid (12.1 g, 95% yield). HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~13~H~12~^79^Br^35^ClN~3~O~3~: 371.97507; found: 371.97488. ^1^H NMR (400 MHz, CDCl~3~): δ, 8.23 (s, 1H), 7.24--7.22 (d, *J* = 8.4, 2H), 6.93--6.91 (d, *J* = 8.4, 2H), 5.24 (bs, 1H), 4.22--4.21 (d, *J* = 4.8, 2H), 3.82 (s, 3H) ppm. ^13^C NMR (100 MHz, CDCl~3~): δ, 160.1 (Cq), 149.3, 143.4 (Cq), 143.3 (Cq), 129.7, 127.9 (Cq), 114.8, 109.4 (Cq), 55.5, 47.0 (CH~2~) ppm.

### 5-Bromo-*N*^2^,*N*^2^,*N*^4^-tris(4-methoxybenzyl)-3-nitropyridine-2,4-diamine (**11**) {#sec4.3.4}

A 250 mL Schlenk tube was charged with **10** (12.1 g, 32.6 mmol), bis(4-methoxybenzyl)amine (10.9 g, 42.4 mmol), *n*-butanol (100 mL), and Et~3~N (6 mL, 43.1 mmol). The mixture was heated at 130 °C for 24 h. It was cooled, diluted with EtOAc (400 mL), washed with brine (200 mL), and dried with MgSO~4~. After filtration, the solution was concentrated to give a dark residue that was purified by column chromatography on silica gel, eluting with 0--15% EtOAc in hexanes to obtain **11** as a red foam (17.6 g, 92% yield). HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~29~H~30~^79^BrN~4~O~5~: 593.13999; found: 593.13894. ^1^H NMR (400 MHz, CDCl~3~): δ, 8.09 (s, 1H), 7.21--7.18 (d, *J* = 8.8, 2H), 7.08--7.05 (d, *J* = 8.8, 4H), 6.88--6.86 (d, *J* = 8.8, 2H), 6.82--6.80 (d, *J* = 8.8, 4H), 6.14--6.12 (t, *J* = 4.8, 1H), 4.46--4.45 (d, *J* = 4.8, 2H), 4.29 (s, 4H), 3.782 (s, 3H), 3.778 (s, 6H) ppm. ^13^C NMR (100 MHz, CDCl~3~): δ, 159.6 (Cq), 159.0 (Cq), 155.5 (Cq), 151.1, 146.5 (Cq), 129.7, 129.5 (Cq), 129.4, 129.2 (Cq), 126.0 (Cq), 114.5, 113.9, 99.6 (Cq), 55.4, 55.3, 53.7 (CH~2~), 49.2 (CH~2~) ppm.

### 5-Bromo-*N*^2^,*N*^2^,*N*^4^-tris(4-methoxybenzyl)pyridine-2,3,4-triamine (**12**) {#sec4.3.5}

A 1 L round-bottom flask was charged with **11** (16.7 g, 28.2 mmol), ethanol (600 mL), and deionized water (300 mL), followed by Na~2~S~2~O~4~ (9.81 g, 56.4 mmol, 2 equiv). The mixture was heated at 85 °C under reflux condenser. Additional sodium hydrosulfite was added at 30 min intervals (overall, 4 × 2 equiv) over 2.5 h. The mixture was then concentrated in vacuo to remove most of ethanol and diluted with EtOAc (200 mL). It was carefully neutralized with solid NaHCO~3~ (effervescence!) with vigorous stirring. The organic layer was separated, the aqueous phase was additionally extracted with EtOAc (2 × 150 mL), and the combined organics were washed with brine (100 mL) and dried with MgSO~4~. After filtration and concentration, the residue was purified by column chromatography on silica gel, eluting with 0--60% EtOAc in hexanes, and the product was additionally triturated with hexanes containing some EtOAc to obtain **12** as a cream solid in 59% yield (9.4 g). This compound is somewhat unstable and should be used within few days. HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~29~H~32~^79^BrN~4~O~3~: 563.1658; found: 563.16396. ^1^H NMR (400 MHz, CDCl~3~): δ, 7.77 (s, 1H), 7.22--7.20 (d, *J* = 8.8, 2H), 7.10--7.08 (d, *J* = 8.8, 4H), 6.84--6.82 (d, *J* = 8.8, 2H), 6.81--6.79 (d, *J* = 8.8, 4H), 4.25--4.24 (d, *J* = 6.8, 2H), 4.14 (s, 4H), 4.00 (bs, 2H), 3.78 (s, 9H) ppm. ^13^C NMR (100 MHz, CDCl~3~): δ, 159.1 (Cq), 158.8 (Cq), 150.2 (Cq), 139.8 (Cq), 138.3, 131.6 (Cq), 130.7 (Cq), 130.1, 129.9 (Cq), 129.2, 114.1, 113.7, 110.8 (Cq), 55.36, 55.34, 53.5 (CH~2~), 48.7 (CH~2~) ppm.

### 7-Bromo-*N*,*N*,1-tris(4-methoxybenzyl)-1*H*-imidazo-\[4,5-*c*\]pyridin-4-amine (**13**) {#sec4.3.6}

A 250 mL Schlenk tube was charged with **12** (9.4 g, 16.7 mmol) and trimethyl orthoformate (150 mL). The mixture was heated at 110 °C for 24 h and concentrated in vacuo. The remaining residue was dissolved in the smallest possible volume of EtOAc, and hexanes was carefully added dropwise with stirring to cause slight turbidity. The mixture was chilled in the freezer at −20 °C overnight, and the resulting precipitate was filtered, washed with hexanes, and dried in air to give **13** as an off-white to cream solid in 94% yield (8.96 g). HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~30~H~30~^81^BrN~4~O~3~: 575.1481; found: 575.14530. ^1^H NMR (399.8 MHz, CDCl~3~): δ, 7.97 (s, 1H), 7.62 (s, 1H), 7.22--7.20 (d, *J* = 8.8, 4H), 7.13--7.10 (d, *J* = 8.8, 2H), 6.90--6.87 (d, *J* = 8.8, 2H), 6.84--6.82 (d, *J* = 8.8, 4H), 5.65 (s, 2H), 5.13 (s, 4H), 3.80 (s, 3H), 3.78 (s, 6H) ppm. ^13^C NMR (100 MHz, CDCl~3~): δ, 159.6 (Cq), 158.7 (Cq), 151.6 (Cq), 143.1, 141.0, 136.6 (Cq), 131.2 (Cq), 129.5 (Cq), 129.2, 128.5, 128.4 (Cq), 114.5, 113.9, 89.0 (Cq), 55.44, 55.38, 49.8 (CH~2~), 49.0 (CH~2~) ppm.

Cross-Coupling Reactions of **13** {#sec4.4}
----------------------------------

### General Conditions A^[@ref43]^ {#sec4.4.1}

A solution of **13** (0.25--3.5 mmol, 1 equiv) in 2:1 dioxane/deionized water mixture (ca. 12 mL/mmol) was placed in a Schlenk tube or a vial equipped with septa. The mixture was bubbled with argon for ca. 1 min/mL. Aryl or vinylboronic acid (1.5 equiv), tetrakis(triphenylphosphine)palladium (0) (0.1 equiv), and anhydrous cesium carbonate (2 equiv) were added, and the mixture was bubbled with argon for few more minutes and heated at 90 °C for 6--16 h with vigorous stirring. It was cooled and diluted with equal volumes of CH~2~Cl~2~ and 1:1 water/brine, the phases were separated, and the aqueous phase was extracted twice with CH~2~Cl~2~. The combined organic extracts were dried with MgSO~4~. After filtration and concentration, the products were purified by column chromatography on silica gel eluting with 0--20% EtOAc in hexanes.

### General Conditions B^[@ref44]^ {#sec4.4.2}

To a flame-dried vial equipped with septa, dry dioxane (ca. 7 mL/mmol) was added and bubbled with argon for ca. 1 min/mL. Compound **13** (0.25--3.5 mmol, 1 equiv), alkylboronic acid (1.1--1.5 equiv), tetrakis(triphenylphosphine)palladium(0) (0.1 equiv), and anhydrous potassium carbonate (3 equiv) were added. The mixture was bubbled with argon for few more minutes and heated at 90 °C for 72 h with vigorous stirring. It was cooled and filtered through Celite and washed with CH~2~Cl~2~. After concentration, the products were purified by column chromatography on silica gel eluting with 0--20% EtOAc in hexanes.

### General Conditions C^[@ref45]^ {#sec4.4.3}

To a flame-dried vial equipped with septa, dry acetonitrile (3.5 mL) was added and bubbled with argon for ca. 1 min/mL. Compound **13** (0.25 mmol, 1 equiv), triphenylphosphine (0.5 equiv), and palladium(II) acetate (0.1 equiv) were added, followed by an olefin (5 equiv) and triethylamine (7 equiv), and the mixture was bubbled with argon for few more minutes and heated at 90 °C for 36 h with vigorous stirring. It was cooled, diluted with CH~2~Cl~2~ (50 mL), washed with aqueous NH~4~Cl (2 × 25 mL), and dried with MgSO~4~. After filtration and concentration, the products were purified by column chromatography on silica gel eluting with 0--40% EtOAc in hexanes. The procedure for separation of dehalogenated byproduct: the crude mixture obtained after the extractive workup was redissolved in CH~2~Cl~2~ (10 mL), and NIS (ca. 0.6 equiv) was added. After stirring at room temperature for 2 h, the mixture was diluted with CH~2~Cl~2~ (50 mL), washed with brine containing sodium thiosulfate (25 mL), and dried with MgSO~4~. After filtration and concentration, the products were purified by column chromatography on silica gel eluting with 0--40% EtOAc in hexanes. **13-I** eluted first.

### General Conditions D^[@ref23]^ {#sec4.4.4}

To a flame-dried vial equipped with septa, dry DMF (5 mL) and triethylamine (2.5 mL) were added and bubbled with argon for ca. 1 min/mL. Compound **13** (0.25 mmol, 1 equiv), CuI (0.1 equiv), and bis(triphenylphosphine)palladium(II) dichloride (0.1 equiv) were added, followed by phenylacetylene (1.5 equiv). The mixture was bubbled with argon for few more minutes and heated at 80 °C for 24 h with vigorous stirring. It was cooled, quenched with saturated aqueous NH~4~Cl (10 mL), diluted with EtOAc (10 mL), washed with brine (3 × 10 mL), and dried with MgSO~4~. After filtration and concentration, the products were purified by column chromatography on silica gel eluting with 0--20% EtOAc in hexanes.

### General Conditions E^[@ref46]^ {#sec4.4.5}

To a flame-dried vial equipped with septa, dry THF (6 mL) was added and bubbled with argon for ca. 1 min/mL. Compound **13** (0.25 mmol, 1 equiv) and tetrakis(triphenylphosphine)palladium(0) (0.1 equiv) were added, followed by trimethylaluminum or benzylmagnesium chloride solutions (3--3.3 equiv), and the mixture was stirred at room temperature for 15 min and then heated at 80 °C for 4 h with vigorous stirring. It was cooled, carefully quenched with Et~2~O (30 mL), washed with saturated aqueous NH~4~Cl (30 mL), and dried with MgSO~4~. After filtration and concentration, the products were purified by column chromatography on silica gel eluting with 0--40% EtOAc in hexanes.

### General Conditions F^[@ref58]^ {#sec4.4.6}

To a flame-dried vial equipped with septa, was added a solution of ZnCl~2~ (0.5 M in THF, 5.7 equiv), followed by dropwise addition of Grignard reagent solution (8.6 equiv), and the mixture was stirred under argon for 1 h. Then, compound **13** (0.175--0.7 mmol, 1 equiv) and \[1,1′-bis(diphenylphosphino)ferrocene\]-dichloropalladium(II) (0.1 equiv) were added, and the mixture was stirred at room temperature under argon for overall 21--29 h. It was carefully quenched with Et~2~O (30--50 mL), washed with equal volume of saturated aqueous NH~4~Cl, and dried with MgSO~4~. After filtration and concentration, the products were purified by column chromatography on silica gel eluting with 0--20% EtOAc in hexanes.

### General Conditions G^[@ref48]^ {#sec4.4.7}

To a flame-dried vial equipped with septa, were added sequentially NiI~2~ (0.065 mmol, 0.13 equiv), 4,4′-dimethoxy-2,2′-bipyridine (0.05 mmol, 0.1 equiv), NaI (0.125 mmol, 0.25 equiv), **13** (0.5 mmol, 1 equiv), dry DMA (2 mL), pyridine (5 μL), ethyl 4-bromobutyrate (0.55 mmol, 1.1 equiv), and Zn powder (1 mmol, 2 equiv). The headspace of the vial was flushed with argon for 1 min. The reaction mixture was stirred at room temperature for 5 min and then heated at 60 °C for 20 h with vigorous stirring. It was cooled, diluted with EtOAc (50 mL), washed with brine (3 × 25 mL), and dried with MgSO~4~. The crude mixtures were subjected to the same procedure of dehalogenated byproduct separation as described under general conditions C. The products were purified by column chromatography on silica gel eluting with 0--40% EtOAc in hexanes. **13-I** eluted first.

Characterization Data for Compounds from [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} {#sec4.5}
------------------------------------------------------------------------------------------------------

### *N*,*N*,1-Tris(4-methoxybenzyl)-7-phenyl-1*H*-imidazo\[4,5-*c*\]pyridin-4-amine (**14a**) {#sec4.5.1}

General conditions A, 6 h, 335 mg, 91%. Yellowish syrup. HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~36~H~35~N~4~O~3~: 571.27093; found: 571.26842. ^1^H NMR (400 MHz, CDCl~3~): δ, 7.78 (s, 1H), 7.68 (s, 1H), 7.36--7.34 (m, 3H), 7.29--7.27 (d, *J* = 8.8, 4H), 7.27--7.25 (m, 2H), 6.87--6.85 (d, *J* = 8.8, 2H), 6.71--6.69 (d, *J* = 8.8, 2H), 6.56--6.54 (d, *J* = 8.8, 2H), 5.23 (s, 4H), 4.94 (s, 2H), 3.80 (s, 6H), 3.76 (s, 3H) ppm. ^13^C NMR (100 MHz, CDCl~3~): δ, 159.6 (Cq), 158.7 (Cq), 151.6 (Cq), 141.8, 141.0, 137.7 (Cq), 136.7 (Cq), 131.6 (Cq), 130.4, 129.3, 128.2, 128.10, 128.06 (Cq), 128.0 (Cq), 127.4, 114.1, 113.9, 113.8 (Cq), 55.40, 55.38, 49.64 (CH~2~), 49.55 (CH~2~) ppm.

### (*E*)*-N*,*N*,1-Tris(4-methoxybenzyl)-7-styryl-1*H*-imidazo\[4,5-*c*\]pyridin-4-amine (**14b**) {#sec4.5.2}

General conditions A, 16 h, 123 mg, 79%. General conditions C, 36 h, 83 mg, 53%. Tan solid. HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~38~H~37~N~4~O~3~: 597.28658; found: 597.28453. ^1^H NMR (400 MHz, CDCl~3~): δ, 8.10 (s, 1H). 7.69 (s, 1H), 7.32--7.23 (m, 8H), 7.20--7.16 (d, *J* = 15.6, 1H), 7.06--7.04 (d, *J* = 8.8, 2H), 6.92--6.89 (d, *J* = 8.8, 2H), 6.86--6.82 (m, 5H), 5.46 (s, 2H), 5.22 (s, 4H), 3.804 (s, 3H), 3.796 (s, 6H) ppm. ^13^C NMR (100 MHz, CDCl~3~): δ, 159.6 (Cq), 158.7 (Cq), 151.7 (Cq), 141.0, 139.6, 138.1 (Cq), 137.8 (Cq), 131.5 (Cq), 129.3, 129.0, 128.8, 128.6 (Cq), 127.8 (Cq), 127.6, 127.4, 126.4, 122.2, 114.7, 113.9, 110.8 (Cq), 55.5, 55.4, 49.8 (CH~2~), 49.7 (CH~2~) ppm.

### *N*,*N*,1-Tris(4-methoxybenzyl)-7-phenethyl-1*H*-imidazo\[4,5-*c*\]pyridin-4-amine (**14c**) {#sec4.5.3}

General conditions B, 72 h, 55 mg, 35%. General conditions F, 29 h, 327 mg, 77%. Colorless syrup. HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~38~H~39~N~4~O~3~: 599.30224; found: 599.29971. ^1^H NMR (400 MHz, CDCl~3~): δ, 7.76 (s, 1H), 7.63 (s, 1H), 7.31 −7.20 (m, 3H), 7.26--7.24 (d, *J* = 8.8, 4H), 7.10--7.08 (d, *J* = 8.8, 4H), 6.94--6.92 (d, *J* = 8.8, 2H), 6.87--6.84 (m, 2H), 6.86--6.83 (d, *J* = 8.8, 2H), 5.34 (s, 2H), 5.18 (s, 4H), 3.80 (s, 6H), 3.79 (s, 3H), 3.02--2.88 (m, 4H) ppm. ^13^C NMR (100 MHz, CDCl~3~): δ, 159.6 (Cq), 158.6 (Cq), 151.4 (Cq), 141.4, 141.3 (Cq), 141.0, 138.8 (Cq), 131.7 (Cq), 129.3, 128.59, 128.56 (Cq), 128.48, 127.6, 126.3, 114.7, 113.8, 110.9 (Cq), 55.44, 55.36, 49.7 (CH~2~), 49.4 (CH~2~), 38.5 (CH~2~), 30.7 (CH~2~) ppm. For other conditions tested, see [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01159/suppl_file/ao7b01159_si_001.pdf).

### *N*,*N*,1-Tris(4-methoxybenzyl)-1*H*-imidazo\[4,5-*c*\]pyridin-4-amine (**13-H**) {#sec4.5.4}

General conditions B, 72 h, 34 mg, 30%. Yellowish syrup. HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~30~H~31~N~4~O~3~: 495.23964; found: 495.23722. ^1^H NMR (400 MHz, CDCl~3~): δ, 7.96--7.94 (d, *J* = 5.6, 1H), 7.70 (s, 1H), 7.25--7.23 (d, *J* = 8.8, 4H), 7.16--7.14 (d, *J* = 8.8, 2H), 6.90--6.87 (d, *J* = 8.8, 2H), 6.84--6.82 (d, *J* = 8.8, 4H), 6.64--6.62 (d, *J* = 5.6, 1H), 5.21 (s, 2H), 5.17 (s, 4H), 3.80 (s, 3H), 3.78 (s, 6H) ppm. ^13^C NMR (100 MHz, CDCl~3~): δ, 159.8 (Cq), 158.6 (Cq), 152.3 (Cq), 141.1, 140.5 (Cq), 139.2, 131.5 (Cq), 129.2, 129.0, 127.9 (Cq), 127.3 (Cq), 114.6, 113.9, 96.2, 55.45, 55.36, 49.4 (CH~2~), 48.6 (CH~2~) ppm.

### 7-Iodo-*N*,*N*,1-tris(4-methoxybenzyl)-1*H*-imidazo\[4,5-*c*\]pyridin-4-amine (**13-I**) {#sec4.5.5}

General conditions C, 36 h, 50 mg, 31%. General conditions G, 20 h, 110 mg, 36%. Yellowish foam. HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~30~H~30~IN~4~O~3~: 621.13629; found: 621.13419. ^1^H NMR (400 MHz, CDCl~3~): δ, 8.17 (s, 1H), 7.62 (s, 1H), 7.23--7.20 (d, *J* = 8.8, 4H), 7.08--7.06 (d, *J* = 8.8, 2H), 6.90--6.88 (d, *J* = 8.8, 2H), 6.84--6.82 (d, *J* = 8.8, 4H), 5.67 (s, 2H), 5.15 (s, 4H), 3.80 (s, 3H), 3.79 (s, 6H) ppm. ^13^C NMR (100 MHz, CDCl~3~): δ, 159.6 (Cq), 158.7 (Cq), 152.3 (Cq), 149.2, 141.4, 138.5 (Cq), 131.2 (Cq), 129.8 (Cq), 129.2, 128.5, 128.4 (Cq), 114.5, 113.9, 56.0 (Cq), 55.44, 55.38, 49.8 (CH~2~), 48.5 (CH~2~) ppm.

### 7-Ethyl-*N*,*N*,1-tris(4-methoxybenzyl)-1*H*-imidazo\[4,5-*c*\]pyridin-4-amine (**14d**) {#sec4.5.6}

General conditions B, 72 h, 284 mg, 31%. General conditions F, 25 h, 69 mg, 76%. Colorless syrup. HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~32~H~35~N~4~O~3~: 523.27093; found: 523.26894. ^1^H NMR (400 MHz, CDCl~3~): δ, 7.73 (s, 1H), 7.64 (s, 1H), 7.24--7.21 (d, *J* = 8.8, 4H), 6.99--6.97 (d, *J* = 8.8, 2H), 6.88--6.86 (d, *J* = 8.8, 2H), 6.83--6.81 (d, *J* = 8.8, 4H), 5.44 (s, 2H), 5.15 (s, 4H), 3.79 (s, 3H), 3.78 (s, 6H), 2.77--2.71 (q, *J* = 7.6, 2H), 1.25--1.21 (t, *J* = 7.6, 3H) ppm. ^13^C NMR (100 MHz, CDCl~3~): δ, 159.6 (Cq), 158.6 (Cq), 151.3 (Cq), 141.0, 140.5, 138.8 (Cq), 131.8 (Cq), 129.3, 128.8 (Cq), 128.6 (Cq), 127.6, 114.6, 113.8, 113.2 (Cq), 55.5, 55.4, 49.7 (CH~2~), 49.6 (CH~2~), 22.0 (CH~2~), 16.2 ppm.

### 7-Isobutyl-*N*,*N*,1-tris(4-methoxybenzyl)-1*H*-imidazo\[4,5-*c*\]pyridin-4-amine (**14e**) {#sec4.5.7}

General conditions B, 72 h, 658 mg, 29%. General conditions F, 21 h, 327 mg, 85%. Yellowish syrup. HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~34~H~39~N~4~O~3~: 551.30224; found: 551.29987. ^1^H NMR (400 MHz, CDCl~3~): δ, 7.67 (s, 1H), 7.63 (s, 1H), 7.24--7.21 (d, *J* = 8.8, 4H), 6.98--6.95 (d, *J* = 8.8, 2H), 6.88--6.86 (d, *J* = 8.8, 2H), 6.84--6.82 (d, *J* = 8.8, 4H), 5.40 (s, 2H), 5.15 (s, 4H), 3.79 (s, 3H), 3.78 (s, 6H), 2.51--2.49 (d, *J* = 7.2, 2H), 1.84--1.74 (septet, *J* = 6.4, 1H), 0.95--0.94 (d, *J* = 6.4, 6H) ppm. ^13^C NMR (100 MHz, CDCl~3~): δ, 159.6 (Cq), 158.6 (Cq), 151.4 (Cq), 142.3, 140.9, 139.0 (Cq), 131.8 (Cq), 129.3, 128.8 (Cq), 128.7 (Cq), 127.6, 114.7, 113.8, 110.6 (Cq), 55.5, 55.4, 49.6 (CH~2~), 49.5 (CH~2~), 38.2 (CH~2~), 30.7, 22.4 ppm.

### Methyl (*E*)-3-(4-(Bis(4-methoxybenzyl)amino)-1-(4-methoxybenzyl)-1*H*-imidazo\[4,5-*c*\]pyridin-7-yl)acrylate (**14f**) {#sec4.5.8}

General conditions C, 36 h, 86 mg, 57%. Yellowish syrup. HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~34~H~35~N~4~O~5~: 579.26077; found: 579.25862. ^1^H NMR (400 MHz, CDCl~3~): δ, 8.23 (s, 1H), 8.05--8.01 (d, *J* = 15.6, 1H), 7.69 (s, 1H), 7.24--7.22 (d, *J* = 8.8, 4H), 7.12--7.09 (d, *J* = 8.8, 2H), 6.90--6.88 (d, *J* = 8.8, 2H), 6.85--6.83 (d, *J* = 8.8, 4H), 6.26--6.22 (d, *J* = 15.6, 1H), 5.44 (s, 2H), 5.23 (s, 4H), 3.79--3.78 (overlapped s, 12H) ppm. ^13^C NMR (100 MHz, CDCl~3~): δ, 167.8 (Cq), 159.8 (Cq), 158.8 (Cq), 152.8 (Cq), 141.3, 138.8, 138.0 (Cq), 130.9 (Cq), 129.4, 129.2, 128.2 (Cq), 127.6 (Cq), 127.3 (Cq), 114.6, 114.5, 114.0, 107.6 (Cq), 55.41, 55.36, 51.6, 50.4 (CH~2~), 49.7 (CH~2~) ppm.

### *N*,*N*,1-Tris(4-methoxybenzyl)-7-(phenylethynyl)-1*H*-imidazo\[4,5-*c*\]pyridin-4-amine (**14g**) {#sec4.5.9}

General conditions D, 20 h, 138 mg, 89%. Brown syrup. HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~38~H~35~N~4~O~3~: 595.27093; found: 595.26894. ^1^H NMR (400 MHz, CDCl~3~): δ, 8.22 (s, 1H), 7.67 (s, 1H), 7.39--7.37 (m, 2H), 7.33--7.30 (m, 3H), 7.26--7.24 (d, *J* = 8.4, 2H), 7.25--7.23 (d, *J* = 8.4, 4H), 6.89--6.87 (d, *J* = 8.4, 2H), 6.86--6.84 (d, *J* = 8.4, 4H), 5.75 (s, 2H), 5.21 (s, 4H), 3.80 (s, 9H) ppm. ^13^C NMR (100 MHz, CDCl~3~): δ, 159.6 (Cq), 158.8 (Cq), 151.9 (Cq), 146.7, 140.3, 138.3 (Cq), 131.1, 129.3, 128.9, 128.8 (Cq), 128.5, 128.0, 127.0 (Cq), 123.7 (Cq), 114.5, 113.9, 93.6 (Cq), 85.1 (Cq), 55.44, 55.38, 49.6 (CH~2~), 48.5 (CH~2~) ppm.

### *N*,*N*,1-Tris(4-methoxybenzyl)-7-methyl-1*H*-imidazo\[4,5-*c*\]pyridin-4-amine (**14h**) {#sec4.5.10}

General conditions E, 4 h, 115 mg, 87%. Yellow syrup. HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~31~H~33~N~4~O~3~: 509.25528; found: 509.25341. ^1^H NMR (400 MHz, CDCl~3~): δ, 7.66 (s, 1H), 7.65 (s, 1H), 7.24--7.21 (d, *J* = 8.4, 4H), 7.00--6.97 (d, *J* = 8.4, 2H), 6.88--6.86 (d, *J* = 8.4, 2H), 6.83--6.81 (d, *J* = 8.4, 2H), 5.45 (s, 2H), 5.15 (s, 4H), 3.79 (s, 3H), 3.78 (s, 6H), 2.35 (s, 3H) ppm. ^13^C NMR (100 MHz, CDCl~3~): δ, 159.5 (Cq), 158.6 (Cq), 151.4 (Cq), 141.5, 140.8, 139.5 (Cq), 131.8 (Cq), 129.3, 129.0, 128.5 (Cq), 127.5, 114.6, 113.8, 106.6 (Cq), 55.44, 55.36, 49.7 (CH~2~), 49.3 (CH~2~), 15.1 ppm.

### 7-Benzyl-*N*,*N*,1-tris(4-methoxybenzyl)-1*H*-imidazo\[4,5-*c*\]pyridin-4-amine (**14i**) {#sec4.5.11}

General conditions E, 4 h, 69 mg, 45%. Brown syrup. HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~37~H~37~N~4~O~3~: 585.286588; found: 585.28433. ^1^H NMR (400 MHz, CDCl~3~): δ, 7.76 (s, 1H), 7.59 (s, 1H), 7.32--7.23 (m, 7H), 7.09--7.08 (d, *J* = 8.8, 2H), 6.87--6.82 (m, 8H), 5.22 (s, 4H), 5.05 (s, 2H), 4.00 (s, 2H), 3.80 (s, 9H) ppm. ^13^C NMR (100 MHz, CDCl~3~): δ, 159.5 (Cq), 158.6 (Cq), 151.8 (Cq), 142.9, 141.4 (Cq), 140.9, 139.2 (Cq), 131.6 (Cq), 129.3, 129.0 (Cq), 128.9 (Cq), 128.8, 128.0, 127.2, 126.5, 114.6, 113.8, 108.5 (Cq), 55.42, 55.35, 49.7 (CH~2~), 49.0 (CH~2~), 35.0 (CH~2~) ppm.

### 7-Isopropyl-*N*,*N*,1-tris(4-methoxybenzyl)-1*H*-imidazo\[4,5-*c*\]pyridin-4-amine (**14j**) {#sec4.5.12}

General conditions F, 27 h, 80 mg, 86%. Contains ∼20% of *n*-propyl impurity. Colorless syrup. HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~33~H~37~N~4~O~3~: 537.28658; found: 537.28573. ^1^H NMR (400 MHz, CDCl~3~): δ, 7.89 (s, 1H), 7.63 (s, 1H), 7.25--7.22 (d, *J* = 8.8, 4H), 6.98--6.96 (d, *J* = 8.8, 2H), 6.88--6.86 (d, *J* = 8.8, 2H), 6.84--6.82 (d, *J* = 8.8, 4H), 5.44 (s, 2H), 5.16 (s, 4H), 3.79 (s, 3H), 3.78 (s, 6H), 3.30--3.20 (septet, *J* = 6.8, 1H), 1.25--1.24 (d, *J* = 6.4, 6H) ppm. ^13^C NMR (100 MHz, CDCl~3~): δ, 159.6 (Cq), 158.6 (Cq), 151.0 (Cq), 141.4, 138.1 (Cq), 138.0, 131.8 (Cq), 129.3, 128.7 (Cq), 128.6 (Cq), 127.6, 118.3 (Cq), 114.6, 113.8, 55.45, 55.36, 50.0 (CH~2~), 49.7 (CH~2~), 26.3, 24.3 ppm.

### Ethyl 4-(4-(Bis(4-methoxybenzyl)amino)-1-(4-methoxybenzyl)-1*H*-imidazo\[4,5-*c*\]pyridin-7-yl)butanoate (**14k**) {#sec4.5.13}

General conditions G, 20 h, 100 mg, 32%. Colorless syrup. HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~36~H~41~N~4~O~5~: 609.30773; found: 609.30580. ^1^H NMR (400 MHz, CDCl~3~): δ, 7.69 (s, 1H), 7.65 (s, 1H), 7.24--7.22 (d, *J* = 8.8, 4H), 6.98--6.96 (d, *J* = 8.8, 2H), 6.87--6.85 (d, *J* = 8.8, 2H), 6.84--6.82 (d, *J* = 8.8, 4H), 5.47 (s, 2H), 5.16 (s, 4H), 4.14--4.08 (q, *J* = 7.2, 2H), 3.78 (overlapped s, 9H), 2.71--2.68 (m, 2H), 2.37--2.33 (t, *J* = 7.2, 2H), 1.91--1.86 (m, 2H), 1.26--1.22 (t, *J* = 7.2, 3H) ppm. ^13^C NMR (100 MHz, CDCl~3~): δ, 173.5 (Cq), 159.5 (Cq), 158.6 (Cq), 151.4 (Cq), 141.6, 141.1, 138.7 (Cq), 131.7 (Cq), 129.3, 128.8 (Cq), 128.7 (Cq), 127.5, 114.6, 113.8, 110.6 (Cq), 60.5 (CH~2~), 55.42, 55.36, 49.6 (CH~2~), 49.4 (CH~2~), 33.7 (CH~2~), 28.4 (CH~2~), 27.4 (CH~2~), 14.4 ppm.

Synthesis of Phosphoramidites **20i**, **20d**, **and 20e** and Attempted Synthesis of **20a** {#sec4.6}
----------------------------------------------------------------------------------------------

### 7-Benzyl-1*H*-imidazo\[4,5*-c*\]pyridin-4-amine, Trifluoroacetic Acid (TFA) Salt (**15i**) {#sec4.6.1}

This compound was synthesized according to the modified general procedure.^[@ref52]^ A solution of **14i** (589 mg, 1 mmol) in TFA (6 mL) was placed in a 100 mL pressure tube, anisole (0.65 mL, 6 equiv) was added, and the mixture was heated at 70 °C for 24 h with vigorous stirring. It was cooled and concentrated under reduced pressure. The residue was coevaporated with toluene (3 × 25 mL) to obtain **15i** (ca. 0.34 g, quantitative) as an oil that was taken into next step without further purification.

### 1-(7-Benzyl-1*H*-imidazo\[4,5-*c*\]pyridin-4-yl)-3,3,4,4-tetramethylpyrrolidine-2,5-dione (**16i**) {#sec4.6.2}

This compound was synthesized according to the reported general procedure.^[@ref53]^ A solution of **15i** (0.34 g, 1 mmol) in pyridine (10 mL) was placed in a 100 mL Schlenk flask. Tetramethylsuccinic anhydride (M~4~SA)^[@ref59]^ (0.312 g, 2 mmol) and DBU (0.6 mL, 4 mmol) were added, and the mixture was heated at 120 °C under argon for 20 h with vigorous stirring. It was cooled and concentrated under reduced pressure. The residue was coevaporated with toluene (3 × 25 mL). The product was purified by column chromatography on silica gel eluting with 0--5% MeOH in CH~2~Cl~2~ to give a cream foam. It was taken in SOCl~2~ (10 mL), heated at 80 °C for 2 h, cooled and concentrated under reduced pressure. The residue was coevaporated with EtOAc (3 × 25 mL). The product was purified by column chromatography on silica gel eluting with 0--5% MeOH in CH~2~Cl~2~ to give **16i** as a cream foam in 57% yield (0.208 g). HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~21~H~23~N~4~O~2~: 363.18212; found: 363.18045. ^1^H NMR (400 MHz, CD~3~OD): δ, 8.36 (s, 1H), 8.12 (s, 1H), 7.29--7.20 (m, 5H), 4.35 (s, 2H), 1.37 (bs, 12H) ppm. ^13^C NMR (100 MHz, CD~3~OD): δ, 183.4, 146.2, 141.8, 139.7, 137.5, 129.8, 127.7, 124.7, 118.3, 35.5, 21.8 ppm.

### (2*R*,3*S*,5*R*)-5-(7-Benzyl-4-(3,3,4,4-tetramethyl-2,5-dioxopyrrolidin-1-yl)-1*H*-imidazo\[4,5-*c*\]pyridin-1-yl)-2-(((4-methylbenzoyl)oxy)methyl)tetrahydrofuran-3-yl 4-Methylbenzoate (**17i**) {#sec4.6.3}

This compound was synthesized according to the reported general procedure.^[@ref53]^ To a solution of **16i** (0.19 g, 0.52 mmol) in dry CH~3~CN (25 mL) in a 100 mL round-bottom flask, 60% NaH in oil (42 mg, 1.05 mmol) was added, and the mixture was vigorously stirred at room temperature under argon for 45 min. 1-(α)-Chloro-3,5-di-*O*-(*p*-toluoyl)-2-deoxy-[d]{.smallcaps}-ribose (0.368 g, 0.94 mmol) was subsequently added in one portion, and the stirring was continued at room temperature for 4.5 h. The mixture was filtered through Celite and concentrated. The product was purified by column chromatography on silica gel eluting with 50% EtOAc in hexanes. Compound **17i** was obtained as a yellowish syrup in 39% yield (0.145 g). HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~42~H~43~N~4~O~7~: 715.31322; found: 715.31184. ^1^H NMR (400 MHz, CDCl~3~): δ, 8.32 (s, 1H), 8.19 (s, 1H), 7.92--7.90 (d, *J* = 8.4, 2H), 7.87--7.85 (d, *J* = 8.4, 2H), 7.34--7.32 (d, *J* = 8.4, 2H), 7.92--7.90 (d, *J* = 8.4, 2H), 7.14--7.11 (m, 3H), 7.06--7.04 (m, 2H), 6.20--6.17 (dd, *J*~1~ = 5.2, *J*~2~ = 9.2, 1H), 5.54--5.53 (m, 1H), 4.60--4.49 (m, 4H), 4.38--4.34 (AB/2, *J* = 16.8, 1H), 2.49 (s, 3H), 2.46--2.42 (m, 1H), 2.40 (s, 3H), 2.06--2.01 (m, 1H), 1.39 (bs, 1H) ppm. ^13^C NMR (100 MHz, CDCl~3~): δ, 181.6 (Cq), 166.2 (Cq), 165.8 (Cq), 144.8 (Cq), 144.6, 144.4 (Cq), 142.3, 139.6 (Cq), 138.7 (Cq), 138.6 (Cq), 137.5 (Cq), 130.0, 129.8, 129.54, 129.47, 129.2, 128.1, 127.1, 126.6 (Cq), 126.5 (Cq), 120.0 (Cq), 85.8, 82.7, 74.8, 64.3 (CH~2~), 48.1 (Cq), 39.4 (CH~2~), 35.8 (CH~2~), 21.9, 21.8, 21.7, 21.5 ppm. For the critical NOESY correlations, see [Figure S1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01159/suppl_file/ao7b01159_si_001.pdf) and copies of spectra ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01159/suppl_file/ao7b01159_si_001.pdf)).

### 1-(7-Benzyl-1-((2*R*,4*S*,5*R*)-4-hydroxy-5-(hydroxylmethyl)tetrahydrofuran-2-yl)-1*H*-imidazo\[4,5-*c*\]pyridin-4-yl)-3,3,4,4-tetramethylpyrrolidine-2,5-dione (**18i**) {#sec4.6.4}

This compound was synthesized according to the general procedure.^[@ref53]^ To a solution of **17i** (0.14 g, 0.20 mmol) in dry MeOH (4 mL) in a 25 mL round-bottom flask, NaOMe (32 mg, 0.60 mmol) was added. The mixture was stirred at room temperature under argon for 2 h and concentrated in vacuo. The product was purified by column chromatography on silica gel eluting with 0--10% MeOH in dichloromethane to obtain **18i** as an off-white solid in 66% yield (62 mg). HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~26~H~31~N~4~O~5~: 479.22948; found: 479.22931. ^1^H NMR (400 MHz, CD~3~OD): δ, 8.69 (s, 1H), 8.14 (s, 1H), 7.32--7.14 (m, 5H), 6.35--6.32 (dd, *J*~1~ = 6.4, *J*~2~ = 12.8, 1H), 4.61--4.57 (AB/2, *J* = 16.8, 1H), 4.47--4.30 (AB/2, *J* = 16.8, 1H), 4.46--4.44 (m, 1H), 3.95--3.92 (app q, *J* = 3.6, 1H), 3.73--3.69 (app dd, *J*~1~ = 3.6, *J*~2~ = 12.0, 1H), 3.66--3.62 (app dd, *J*~1~ = 3.6, *J*~2~ = 12.0, 1H), 2.52--2.46 (ddd, *J*~1~ = *J*~2~ = 6.0, *J*~3~ = 12.8, 1H), 2.14--2.08 (ddd, *J*~1~ = 4.4, *J*~2~ = 6.0, *J*~3~ = 10.4, 1H), 1.37 (bs, 12H) ppm. ^13^C NMR (100 MHz, CD~3~OD): δ, 183.4 (Cq), 145.9 (Cq), 144.3, 141.0 (Cq), 140.1 (Cq), 138.6 (Cq), 138.4 (Cq), 130.1, 129.5, 127.9, 123.5 (Cq), 89.2, 87.1, 71.7, 62.6 (CH~2~), 48.9 (Cq), 42.0 (CH~2~), 35.9 (CH~2~), 21.88, 21.84 ppm.

### 1-(7-Benzyl-1-((2*R*,4*S*,5*R*)-5-((bis(4-methoxyphenyl)-(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-2-yl)-1*H*-imidazo\[4,5-*c*\]pyridin-4-yl)-3,3,4,4-tetramethylpyrrolidine-2,5-dione (**19i**) {#sec4.6.5}

This compound was synthesized according to the reported general procedure.^[@ref53]^ To a solution of **18i** (56 mg, 0.12 mmol) in pyridine (2 mL), 4,4′-dimethoxytrityl chloride (DMT-Cl) (155 mg, 0.457 mmol) was added in one portion, and the mixture was stirred at room temperature under argon for 5 h (TLC showed complete conversion). MeOH (0.2 mL) was then added, and the mixture was concentrated in vacuo. The product was purified by column chromatography on silica gel (neutralized with triethylamine) eluting with 5--20% acetone in dichloromethane to obtain **19i** as a colorless solid in 69% yield (63 mg). HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~47~H~49~N~4~O~7~: 781.36017; found: 781.35738. ^1^H NMR (400 MHz, CDCl~3~): δ, 8.24 (s, 1H), 8.10 (s, 1H), 7.38--7.10 (m, 14H), 6.82--6.80 (d, *J* = 8.4, 4H), 6.16--6.12 (dd, *J*~1~ = 6.4, *J*~2~ = 12.4, 1H), 4.50--4.46 (AB/2, *J* = 16.8, 1H), 4.43--4.38 (m, 1H), 4.36--4.32 (AB/2, *J* = 16.8, 1H), 4.01--3.98 (app q, *J* = 4.4, 1H), 3.78 (s, 6H), 3.36--3.32 (app dd, *J*~1~ = 4.4, *J*~2~ = 10.4, 1H), 3.28--3.24 (app dd, *J*~1~ = 4.8, *J*~2~ = 10.4, 1H), 2.6 (bs, 1H), 2.28--2.22 (ddd, *J*~1~ = *J*~2~ = 6.0, *J*~3~ = 13.2, 1H), 1.90--1.84 (ddd, *J*~1~ = *J*~2~ = 5.6, *J*~3~ = 9.6, 1H), 1.39--1.38 (overlapped s, 12H) ppm. ^13^C NMR (100 MHz, CDCl~3~): δ, 181.7 (Cq), 158.7 (Cq), 144.5 (Cq), 144.1, 142.6, 139.4 (Cq), 138.8 (Cq), 138.2 (Cq), 137.6 (Cq), 135.63 (Cq), 135.55 (Cq), 130.12, 130.09, 129.1, 128.6, 128.13, 128.10, 127.11, 127.07, 120.6 (Cq), 113.4, 86.8 (Cq), 85.7, 85.2, 72.0, 63.7 (CH~2~), 55.3, 48.0 (Cq), 41.4 (CH~2~), 35.6 (CH~2~), 21.8, 21.4 ppm.

### (2*R*,3*S*,5*R*)-5-(7-Benzyl-4-(3,3,4,4-tetramethyl-2,5-dioxopyrrolidin-1-yl)-1*H*-imidazo\[4,5-*c*\]pyridin-1-yl)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)tetrahydrofuran-3-yl (2-Cyanoethyl) Diisopropylphosphoramidite (**20i**) {#sec4.6.6}

This compound was synthesized according to the reported general procedure.^[@ref60]^ To a solution of **19i** (62 mg, 0.080 mmol) in dry CH~2~Cl~2~ (2 mL) containing *N*,*N*-diisopropylethylamine (DIEA) (70 μL, 0.4 mmol), 2-cyanoethyl-*N*,*N*-diisopropyl chlorophosphoramidite (40 μL, 0.175 mmol) was added in one portion, and the mixture was stirred at room temperature under argon for 3 h (TLC showed complete conversion). The mixture was concentrated in vacuo at rt, and the product was purified by column chromatography on silica gel (neutralized with triethylamine) eluting with 50% EtOAc in hexanes containing 1% triethylamine, to obtain **20i** as a mixture of diastereomers (colorless solid, *R~f~* ∼ 0.5 in 5% acetone/CH~2~Cl~2~, two close spots visible on TLC) in 49% yield (38 mg). HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~56~H~66~N~6~O~8~P: 981.46801; found: 981.46481. ^1^H NMR (400 MHz, acetone-*d*~6~): δ, 8.40, 8.39 (s, 1H), 8.21, 8.19 (s, 1H), 7.45--7.18 (m, 14H), 6.84--6.80 (m, 4H), 6.40--6.35 (dd, *J*~1~ = 7.0, *J*~2~ = 12.8, 1H), 4.68--4.78 (m, 2H), 4.56--4.52, 4.53--4.49 (AB/2, *J* = 16.4, 1H), 4.28--4.26, 4.24--4.21 (app q, *J* = 4.4, 1H), 3.763, 3.757 (s, 6H), 3.67--3.58 (m, 2H), 3.36--3.32 (m, 2H), 2.91--2.78 (m, 3H), 2.76--2.73 (t, *J* = 6.0, 1H), 2.68--2.65 (t, *J* = 6.0, 1H), 1.35, 1.31 (bs, 12H), 1.21--1.19 (m, 6H), 1.15--1.14, 1.13--1.11 (d, *J* = 6.8, 6H) ppm. ^13^C NMR (100 MHz, acetone-*d*~6~): δ, 181.7, 159.6, 145.9, 144.36, 144.27, 144.02, 143.97, 140.4, 140.08, 140.05, 139.2, 138.8, 136.64, 136.58, 136.52, 130.96, 130.93, 129.7, 129.34, 129.31, 128.97, 128.91, 128.6, 127.6, 127.50, 127.47, 122.3, 122.2, 119.0, 114.0, 87.22, 87.18, 86.6, 86.4, 86.3, 86.2, 74.4, 74.0, 73.8, 64.3, 64.3, 59.7, 59.6, 59.4, 55.5, 55.0, 48.3, 44.06, 43.99, 43.94, 43.86, 40.4, 40.3, 35.5, 24.94, 24.86, 24.82, 22.0, 21.7, 21.4, 20.8, 20.7 ppm. ^31^P NMR (162 MHz, acetone-*d*~6~): δ, 149.8, 149.6 ppm.

### 7-Ethyl-1*H*-imidazo\[4,5*-c*\]pyridin-4-amine, Trifluoroacetic Acid Salt (**15d**) {#sec4.6.7}

This compound was synthesized in a similar fashion to **15i**. A solution of **14d** (750 mg, 1.4 mmol) in TFA (10 mL) was placed in a 100 mL pressure tube, anisole (ca. 1 mL, 6 equiv) was added, and the mixture was heated at 70 °C for 24 h with vigorous stirring. It was cooled and concentrated under reduced pressure. The residue was coevaporated with toluene (3 × 20 mL) to obtain **15d** (ca. 0.4 g, quantitative) as an oil that was taken into next step without further purification.

### 1-(7-Ethyl-1*H*-imidazo\[4,5-*c*\]pyridin-4-yl)-3,3,4,4-tetramethylpyrrolidine-2,5-dione (**16d**) {#sec4.6.8}

This compound was synthesized in a similar fashion to **16i**. A solution of **15d** (0.4 g, 1.4 mmol) in pyridine (15 mL) was placed in a 100 mL Schlenk flask. Tetramethylsuccinic anhydride (M~4~SA) (0.5 g, 3.2 mmol) and DBU (1 mL, 6.7 mmol) were added, and the mixture was heated at 120 °C under argon for 22 h with vigorous stirring. It was cooled and concentrated under reduced pressure. The residue was coevaporated with toluene (3 × 20 mL). The product was purified by column chromatography on silica gel eluting with 0--5% MeOH in CH~2~Cl~2~ to give a cream solid. It was taken in SOCl~2~ (12 mL), heated at 80 °C for 2 h, cooled, and concentrated under reduced pressure. The residue was coevaporated with EtOAc (3 × 20 mL). The product was purified by column chromatography on silica gel eluting with 0--8% MeOH in CH~2~Cl~2~ to give **16d** as a cream solid in 88% yield (0.37 g). HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~16~H~21~N~4~O~2~: 301.16647; found: 301.16501. ^1^H NMR (400 MHz, CD~3~OD): δ, 8.52 (s, 1H), 8.24 (s, 1H), 3.07--3.01 (q, *J* = 7.2, 2H), 1.41--1.37 (t, *J* = 7.2, 3H), 1.37 (bs, 12H) ppm. ^13^C NMR (100 MHz, CD~3~OD): δ, 182.9, 146.9, 143.5, 139.6, 135.4, 135.1, 128.7, 48.9, 23.2, 21.8, 14.5 ppm.

### (2*R*,3*S*,5*R*)-5-(7-Ethyl-4-(3,3,4,4-tetramethyl-2,5-dioxopyrrolidin-1-yl)-1*H*-imidazo\[4,5-*c*\]pyridin-1-yl)-2-(((4-methylbenzoyl)oxy)methyl)tetrahydrofuran-3-yl 4-Methylbenzoate (**17d**) {#sec4.6.9}

This compound was synthesized in a similar fashion to **17i**. To a solution of **16i** (0.35 g, 1.17 mmol) in dry CH~3~CN (60 mL) in a 250 mL round-bottom flask, 60% NaH in oil (100 mg, 2.5 mmol) was added, and the mixture was vigorously stirred at room temperature under argon for 45 min. 1-(α)-Chloro-3,5-di-*O*-(*p*-toluoyl)-2-deoxy-[d]{.smallcaps}-ribose (0.817 g, 2.1 mmol) was subsequently added portionwise over 1 h, and the stirring was continued at room temperature for overall 5 h. The mixture was filtered through Celite and concentrated. The product was purified by column chromatography on silica gel eluting with 0--50% EtOAc in hexanes and concentrated repeatedly with dichloromethane. Compound **17d** was obtained as a yellowish syrup in 65% yield (0.494 g). HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~37~H~41~N~4~O~7~: 653.29757; found: 653.29654. ^1^H NMR (400 MHz, CDCl~3~): δ, 8.27 (s, 1H), 8.25 (s, 1H), 7.92--7.90 (d, *J* = 8.0, 2H), 7.88--7.86 (d, *J* = 8.0, 2H), 7.30--7.28 (d, *J* = 8.4, 2H), 7.24--7.22 (d, *J* = 8.4, 2H), 6.60--6.57 (dd, *J*~1~ = 6.4, *J*~2~ = 12.8, 1H), 5.72--5.68 (m, 1H), 4.67--4.59 (m, 3H), 3.16--3.00 (m, 2H), 2.82--2.79 (dd, *J*~1~ = 4.4, *J*~2~ = 6.8, 2H), 2.44 (s, 3H), 2.40 (s, 3H), 1.43--1.40 (t, *J* = 7.6, 3H), 1.37 (bs, 1H) ppm. ^13^C NMR (100 MHz, CDCl~3~): δ, 181.7 (Cq), 166.3 (Cq), 165.9 (Cq), 144.9 (Cq), 144.4 (Cq), 142.6, 142.0, 138.9 (Cq), 137.6 (Cq), 137.3 (Cq), 130.0, 129.9, 129.8, 129.5, 126.6 (Cq), 126.4 (Cq), 124.2 (Cq), 85.5, 82.7, 74.6, 64.0 (CH~2~), 48.0 (Cq), 39.7 (CH~2~), 22.9 (CH~2~), 21.9, 21.8, 21.7, 21.5, 15.4 ppm. For the critical NOESY correlations, see [Figure S2](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01159/suppl_file/ao7b01159_si_001.pdf) and copies of spectra ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01159/suppl_file/ao7b01159_si_001.pdf)).

### 1-(7-Ethyl-1-((2*R*,4*S*,5*R*)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1*H*-imidazo\[4,5-*c*\]pyridin-4-yl)-3,3,4,4-tetramethylpyrrolidine-2,5-dione (**18d**) {#sec4.6.10}

This compound was synthesized in a similar fashion to **18i**. To a solution of **17d** (0.46 g, 0.7 mmol) in dry MeOH (6 mL) in a 25 mL round-bottom flask, NaOMe (114 mg, 2.11 mmol) was added. The mixture was stirred at room temperature under argon for 2 h and concentrated in vacuo. The product was purified by column chromatography on silica gel eluting with 0--10% MeOH in dichloromethane to obtain **18d** as an off-white solid in 74% yield (218 mg). HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~21~H~29~N~4~O~5~: 417.21383; found: 417.21265. ^1^H NMR (400 MHz, CD~3~OD): δ, 8.74 (s, 1H), 8.20 (s, 1H), 6.63--6.60 (dd, *J*~1~ = 6.4, *J*~2~ = 12.8, 1H), 4.58--4.55 (m, 1H), 4.06--4.03 (app q, *J* = 3.6, 1H), 3.78--3.65 (m, 2H), 3.23--3.12 (app septet, *J* = 3.6, 2H), 2.78--2.72 (m, 1H), 2.60--2.54 (ddd, *J*~1~ = 3.6, *J*~2~ = 6.0, *J*~3~ = 10.4, 1H), 1.44--1.40 (t, *J* = 7.6, 3H), 1.37 (bs, 12H) ppm. ^13^C NMR (100 MHz, CD~3~OD): δ, 183.4 (Cq), 145.8 (Cq), 142.4, 140.4 (Cq), 138.4 (Cq), 137.8 (Cq), 127.2 (Cq), 89.4, 87.2, 72.1, 62.7 (CH~2~), 48.8 (Cq), 42.2 (CH~2~), 23.5 (CH~2~), 21.9, 21.8, 15.7 ppm.

### 1-(1-((2*R*,4*S*,5*R*)-5-((Bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-2-yl)-7-ethyl-1*H*-imidazo\[4,5-*c*\]pyridin-4-yl)-3,3,4,4-tetramethylpyrrolidine-2,5-dione (**19d**) {#sec4.6.11}

This compound was synthesized in a similar fashion to **19i**. To a solution of **18d** (190 mg, 0.457 mmol) in pyridine (3 mL), 4,4′-dimethoxytrityl chloride (DMT-Cl) (217 mg, 0.639 mmol) was added in one portion, and the mixture was stirred at room temperature under argon for 4 h. The mixture was concentrated in vacuo. The product was purified by column chromatography on silica gel (neutralized with triethylamine) eluting with 0--20% acetone in dichloromethane to obtain **19d** as a colorless solid in 33% yield (110 mg). HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~42~H~47~N~4~O~7~: 719.34452; found: 719.34247. ^1^H NMR (400 MHz, CDCl~3~): δ, 8.21 (s, 1H), 8.16 (s, 1H), 7.40--7.38 (d, *J* = 7.2, 2H), 7.30--7.20 (m, 7H), 6.82--6.80 (d, *J* = 9.2, 4H), 6.42--6.39 (dd, *J*~1~ = 6.4, *J*~2~ = 12.4, 1H), 4.54--4.48 (m, 1H), 4.11--4.08 (app q, *J* = 4.4, 1H), 3.77 (s, 6H), 3.38--3.34 (app dd, *J*~1~ = 4.4, *J*~2~ = 10.4, 1H), 3.32--3.29 (app dd, *J*~1~ = 4.8, *J*~2~ = 10.4, 1H), 3.17 (bs, 1H), 3.03--3.00 (app dd, *J*~1~ = 3.2, *J*~2~ = 7.6, 1H), 2.99--2.96 (app dd, *J*~1~ = 3.2, *J*~2~ = 7.6, 1H), 2.46--2.44 (app t, *J* = 6.0, 2H), 1.38--1.37 (overlapped s, 12H), 1.36--1.32 (t, J = 7.2, 3H) ppm. ^13^C NMR (100 MHz, CDCl~3~): δ, 181.8 (Cq), 158.7 (Cq), 144.5 (Cq), 142.6, 141.9, 138.9 (Cq), 137.3 (Cq), 137.2 (Cq), 135.63 (Cq), 135.58 (Cq), 130.1, 128.13, 128.06, 127.1, 124.6 (Cq), 113.4, 86.8 (Cq), 86.0, 85.2, 71.9, 63.7 (CH~2~), 55.3, 48.0 (Cq), 41.7 (CH~2~), 22.7 (CH~2~), 21.8, 21.4, 15.3 ppm.

### (2*R*,3*S*,5*R*)-2-((Bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5-(7-ethyl-4-(3,3,4,4-tetramethyl-2,5-dioxopyrrolidin-1-yl)-1*H*-imidazo\[4,5-*c*\]pyridin-1-yl)tetrahydrofuran-3-yl (2-Cyanoethyl) Diisopropylphosphoramidite (**20d**) {#sec4.6.12}

This compound was synthesized in a similar fashion to **20i**. To a solution of **19d** (105 mg, 0.146 mmol) in dry CH~2~Cl~2~ (4 mL) containing *N*,*N*-diisopropylethylamine (DIEA) (127 μL, 0.731 mmol), 2-cyanoethyl-*N*,*N*-diisopropyl chlorophosphoramidite (40 μL, 0.175 mmol) was added in one portion, and the mixture was stirred at room temperature under argon for 4 h (TLC showed complete conversion). The mixture was concentrated in vacuo at rt, and the product was purified by column chromatography on silica gel (neutralized with triethylamine) eluting with 40--60% EtOAc in hexanes containing 1% triethylamine, to obtain **20d** as a mixture of diastereomers (white foam, Rf ∼0.5 in 5% acetone/CH~2~Cl~2~, two close spots visible on TLC) in 67% yield (90 mg). HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~51~H~64~N~6~O~8~P: 919.45236; found: 919.45047. ^1^H NMR (400 MHz, CDCl~3~): δ, 8.25 (s, 1H), 8.23, 8.19 (s, 1H), 7.40--7.38 (m, 2H), 7.30--7.20 (m, 7H), 6.83--6.79 (m, 4H), 6.49--6.46 (dd, *J*~1~ = 6.8, *J*~2~ = 13.6, 1H), 4.70--4.59 (m, 1H), 4.32--4.24 (m, 1H), 3.78, 3.77 (s, 6H), 3.70--3.53 (m, 3H), 3.32--3.31 (m, 1H), 3.13--2.99 (m, 2H), 2.62--2.59 (t, *J* = 6.4, 1H), 2.57--2.55 (m, 1H), 2.44--2.41 (t, *J* = 6.4, 1H), 1.38, 1.37 (bs, 12H), 1.20--1.17 (m, 9H), 1.13--1.12 (d, *J* = 6.8, 3H) ppm. ^13^C NMR (100 MHz, CDCl~3~): δ, 181.7, 158.7, 144.5, 142.5, 142.4, 139.0, 137.4, 135.63, 135.56, 130.2, 128.3, 128.2, 128.1, 127.1, 124.5, 124.4, 117.5, 113.4, 86.7, 85.8, 85.5, 85.4, 74.1, 73.9, 63.4, 63.2, 58.4, 58.2, 55.38, 55.36, 48.0, 43.61, 43.55, 43.4, 41.0, 24.7, 24.6, 22.9, 21.8, 21.5, 15.6 ppm. ^31^P NMR (162 MHz, CDCl~3~): δ, 150.8, 150.2 ppm.

### 7-Isobutyl-1*H*-imidazo\[4,5-*c*\]pyridin-4-amine, Trifluoroacetic Acid Salt (**15e**) {#sec4.6.13}

This compound was synthesized in a similar fashion to **15i**. A solution of **14e** (1.3 g, 2.4 mmol) in TFA (20 mL) was placed in a 100 mL pressure tube, anisole (1.6 mL, 6 equiv) was added, and the mixture was heated at 70 °C for 24 h with vigorous stirring. It was cooled and concentrated under reduced pressure. The residue was coevaporated with toluene (3 × 20 mL) to obtain **15e** (ca. 0.8 g, quantitative) as an oil that was taken into next step without further purification.

### 1-(7-Isobutyl-1*H*-imidazo\[4,5-*c*\]pyridin-4-yl)-3,3,4,4-tetramethylpyrrolidine-2,5-dione (**16e**) {#sec4.6.14}

This compound was synthesized in a similar fashion to **16i**. A solution of **15e** (ca. 0.8 g, 2.4 mmol) in pyridine (20 mL) was placed in a 100 mL Schlenk flask. Tetramethylsuccinic anhydride (M~4~SA) (0.8 g, 5.1 mmol) and DBU (1.5 mL, 10.0 mmol) were added, and the mixture was heated at 120 °C under argon for 22 h with vigorous stirring. It was cooled and concentrated under reduced pressure. The residue was coevaporated with toluene (3 × 20 mL). The product was purified by column chromatography on silica gel eluting with 0--5% MeOH in CH~2~Cl~2~ to give a cream foam. It was taken in SOCl~2~ (20 mL), heated at 80 °C for 2 h, cooled, and concentrated under reduced pressure. The residue was coevaporated with EtOAc (3 × 20 mL). The product was purified by column chromatography on silica gel eluting with 0--8% MeOH in CH~2~Cl~2~ to give **16e** as a cream foam in 79% yield (0.61 g). HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~18~H~25~N~4~O~2~: 329.19777; found: 329.19608. ^1^H NMR (400 MHz, CD~3~OD): δ, 8.43 (s, 1H), 8.16 (s, 1H), 2.87--2.85 (d, *J* = 7.6, 2H), 2.11--2.05 (app septet, *J* = 6.8, 1H), 1.37 (bs, 12H), 0.99--0.97 (d, *J* = 6.4, 6H) ppm. ^13^C NMR (100 MHz, CD~3~OD): δ, 183.2, 146.4, 143.7, 141.6, 135.8, 135.4, 126.0, 38.9, 30.4, 22.6, 21.9 ppm.

### (2*R*,3*S*,5*R*)-5-(7-Isobutyl-4-(3,3,4,4-tetramethyl-2,5-dioxopyrrolidin-1-yl)-1*H*-imidazo\[4,5-*c*\]pyridin-1-yl)-2-(((4-methylbenzoyl)oxy)methyl)tetrahydrofuran-3-yl 4-Methylbenzoate (**17e**) {#sec4.6.15}

This compound was synthesized in a similar fashion to **17i**. To a solution of **16e** (0.585 g, 1.78 mmol) in dry CH~3~CN (60 mL) in a 250 mL round-bottom flask, 60% NaH in oil (143 mg, 3.57 mmol) was added, and the mixture was vigorously stirred at room temperature under argon for 35 min. 1-(α)-Chloro-3,5-di-*O*-(*p*-toluoyl)-2-deoxy-[d]{.smallcaps}-ribose (1.25 g, 3.21 mmol) was subsequently added portionwise over 1 h, and the stirring was continued at room temperature for overall 4.5 h. The mixture was filtered through Celite and concentrated. The product was purified by column chromatography on silica gel eluting with 0--50% EtOAc in hexanes and concentrated repeatedly with dichloromethane. Compound **17e** was obtained as a yellowish solid in 38% yield (0.465 g). HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~39~H~45~N~4~O~7~: 681.32887; found: 681.32697. ^1^H NMR (400 MHz, CDCl~3~): δ, 8.27 (s, 1H), 8.20 (s, 1H), 7.97--7.95 (d, *J* = 8.0, 2H), 7.92--7.90 (d, *J* = 8.0, 2H), 7.30--7.28 (d, *J* = 8.4, 2H), 7.27--7.25 (d, *J* = 8.4, 2H), 6.59--6.55 (dd, *J*~1~ = 5.2, *J*~2~ = 8.8, 1H), 5.73--5.72 (m, 1H), 4.70--4.61 (m, 3H), 2.98--2.92 (dd, *J*~1~ = 7.2, *J*~2~ = 14.4, 1H), 2.84--2.72 (m, 3H), 2.45 (s, 3H), 2.42 (s, 3H), 1.98--1.88 (app septet, *J* = 6.4, 1H), 1.38 (bs, 1H), 1.05--1.03 (d, *J* = 6.8, 6H) ppm. ^13^C NMR (100 MHz, CDCl~3~): δ, 181.6 (Cq), 166.3 (Cq), 165.9 (Cq), 144.9 (Cq), 144.4 (Cq), 144.1, 142.2, 139.2 (Cq), 137.7 (Cq), 137.4 (Cq), 129.9, 129.8, 129.54, 129.47, 126.6 (Cq), 126.3 (Cq), 121.8 (Cq), 85.4, 82.9, 74.9, 64.2 (CH~2~), 48.0 (Cq), 39.9 (CH~2~), 39.1 (CH~2~), 30.2, 22.5, 21.9, 21.8, 21.7, 21.5 ppm. For the critical NOESY correlations, see [Figure S3](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01159/suppl_file/ao7b01159_si_001.pdf) and copies of spectra ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01159/suppl_file/ao7b01159_si_001.pdf)).

### 1-(1-((2*R*,4*S*,5*R*)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7-isobutyl-1*H*-imidazo\[4,5-*c*\]pyridin-4-yl)-3,3,4,4-tetramethylpyrrolidine-2,5-dione (**18e**) {#sec4.6.16}

This compound was synthesized in a similar fashion to **18i**. To a solution of **17e** (0.46 g, 0.68 mmol) in dry MeOH (7 mL) in a 25 mL round-bottom flask, NaOMe (110 mg, 2.03 mmol) was added. The mixture was stirred at room temperature under argon for 2 h and concentrated in vacuo. The product was purified by column chromatography on silica gel eluting with 0--10% MeOH in dichloromethane to obtain **18e** as an off-white foam in 85% yield (256 mg). HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~23~H~33~N~4~O~5~: 445.24512; found: 445.24381. ^1^H NMR (400 MHz, CD~3~OD): δ, 8.74 (s, 1H), 8.14 (s, 1H), 6.58--6.55 (dd, *J*~1~ = 6.4, *J*~2~ = 12.8, 1H), 4.58--4.55 (dt, *J*~1~ = 3.2, *J*~2~ = 6.8, 1H), 4.06--4.04 (app q, *J* = 3.2, 1H), 3.77--3.73 (app dd, *J*~1~ = 3.6, *J*~2~ = 12.0, 1H), 3.72--3.68 (app dd, *J*~1~ = 3.6, *J*~2~ = 12.0, 1H), 3.06--3.01 (app dd, *J*~1~ = 6.8, *J*~2~ = 14.4, 1H), 2.92--2.86 (app dd, *J*~1~ = 7.2, *J*~2~ = 14.0, 1H), 2.76--2.69 (ddd, *J*~1~ = 5.6, *J*~2~ = 6.8, *J*~3~ = 13.2, 1H), 2.56--2.51 (ddd, *J*~1~ = 3.6, *J*~2~ = 6.0, *J*~3~ = 9.6, 1H), 2.04--1.94 (app septet, *J* = 6.8, 1H), 1.37 (bs, 12H), 1.05--1.03 (d, *J* = 6.8, 6H) ppm. ^13^C NMR (100 MHz, CD~3~OD): δ, 183.4 (Cq), 146.0 (Cq), 144.0, 140.7 (Cq), 138.5 (Cq), 137.9 (Cq), 124.6 (Cq), 89.4, 87.0, 72.3, 62.8 (CH~2~), 48.9 (Cq), 42.3 (CH~2~), 39.4 (CH~2~), 31.1, 22.6, 22.5, 21.9, 21.8 ppm.

### 1-(1-((2*R*,4*S*,5*R*)-5-((Bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-2-yl)-7-isobutyl-1*H*-imidazo\[4,5-*c*\]pyridin-4-yl)-3,3,4,4-tetramethylpyrrolidine-2,5-dione (**19e**) {#sec4.6.17}

This compound was synthesized in a similar fashion to **19i**. To a solution of **18e** (225 mg, 0.507 mmol) in dry pyridine (4 mL), 4,4′-dimethoxytrityl chloride (DMT-Cl) (240 mg, 0.709 mmol) was added in one portion, and the mixture was stirred at room temperature under argon for 4 h. TLC analysis indicated that a lot of starting material remained and then additional DMT-Cl (0.120 g, 0.355 mmol) and cat. 4-dimethylaminopyridine (DMAP) (10 mg) were added. After 14 h, more DMT-Cl (0.120 g, 0.350 mmol), triethylamine (85 μL, 0.608 mmol), and cat. DMAP (10 mg) were added. After 8 h, another portion as above was added, and after 16 h, TLC showed no further conversion (overall 42 h). The mixture was quenched with 200 μL of MeOH, concentrated in vacuo, the residue was taken in AcOEt and filtered, and the filtrate was concentrated in vacuo. The product was purified by column chromatography on silica gel (neutralized with triethylamine) eluting with 0--25% acetone in dichloromethane to obtain **19e** as a colorless foam in 46% yield (175 mg). Further elution with 10% MeOH in dichloromethane yielded the recovered starting material **18e** as a colorless syrup in 45% yield (102 mg). HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~44~H~51~N~4~O~7~: 747.37582; found: 747.37412. ^1^H NMR (400 MHz, CDCl~3~): δ, 8.17 (s, 1H), 8.14 (s, 1H), 7.40--7.38 (d, *J* = 8.8, 2H), 7.30--7.20 (m, 7H), 6.82--6.80 (d, *J* = 8.8, 4H), 6.42--6.38 (dd, *J*~1~ = 6.4, *J*~2~ = 12.8, 1H), 4.52--4.51 (m, 1H), 4.10--4.07 (app q, *J* = 4.4, 1H), 3.77 (s, 6H), 3.38--3.35 (app dd, *J*~1~ = 4.4, *J*~2~ = 10.4, 1H), 3.33--3.29 (app dd, *J*~1~ = 4.8, *J*~2~ = 10.4, 1H), 2.88--2.83 (app dd, *J*~1~ = 7.2, *J*~2~ = 14.4, 1H), 2.75--2.70 (app dd, *J*~1~ = 6.4, *J*~2~ = 14.0, 1H), 2.46--2.41 (m, 2H), 1.90--1.84 (app quintet, *J* = 6.4, 1H), 1.37--1.36 (overlapped s, 12H), 1.01--0.99 (dd, *J*~1~ = 2.4, *J*~2~ = 6.4, 6H) ppm. ^13^C NMR (100 MHz, CDCl~3~): δ, 181.7 (Cq), 158.7 (Cq), 144.5 (Cq), 143.6, 142.7, 139.2 (Cq), 137.5 (Cq), 137.4 (Cq), 135.63 (Cq), 135.58 (Cq), 130.1, 128.2, 128.1, 127.1, 122.2 (Cq), 113.4, 86.8 (Cq), 86.0, 85.0, 72.0, 63.7 (CH~2~), 55.3, 48.0 (Cq), 41.8 (CH~2~), 38.8 (CH~2~), 30.1, 22.5, 22.4, 21.8, 21.4 ppm.

### (2*R*,3*S*,5*R*)-2-((Bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5-(7-isobutyl-4-(3,3,4,4-tetramethyl-2,5-dioxopyrrolidin-1-yl)-1*H*-imidazo\[4,5-*c*\]pyridin-1-yl)tetrahydrofuran-3-yl (2-Cyanoethyl) Diisopropylphosphoramidite (**20e**) {#sec4.6.18}

This compound was synthesized in a similar fashion to **20i**. To a solution of **19e** (105 mg, 0.146 mmol) in dry CH~2~Cl~2~ (5 mL) containing *N*,*N*-diisopropylethylamine (DIEA) (185 μL, 1.07 mmol), 2-cyanoethyl-*N*,*N*-diisopropyl chlorophosphoramidite (105 μL, 0.472 mmol) was added in one portion, and the mixture was stirred at room temperature under argon for 4 h (TLC showed complete conversion). The mixture was concentrated in vacuo at rt, and the product was purified by column chromatography on silica gel (neutralized with triethylamine) eluting with 40--60% EtOAc in hexanes containing 1% triethylamine, to obtain **20e** as a mixture of diastereomers (white foam, *R*~f~ ∼0.5 in 50% EtOAc in hexanes, two close spots visible on TLC) in 59% yield (120 mg). HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~53~H~68~N~6~O~8~P: 947.48366; found: 947.48314. ^1^H NMR (400 MHz, acetone-*d*~6~): δ, 8.43, 8.41 (s, 1H), 8.15 (s, 1H), 7.46--7.41 (m, 2H), 7.33--7.19 (m, 7H), 6.85--6.81 (m, 4H), 6.62--6.58 (dd, *J*~1~ = 6.4, *J*~2~ = 13.2, 1H), 4.86--4.81 (m, 1H), 4.37--4.29 (m, 1H), 3.96--3.82 (m, 1H), 3.77, 3.76 (s, 6H), 3.74--3.66 (m, 2H), 3.39--3.34 (m, 2H), 3.13--3.09 (m, 1H), 3.03--2.96 (m, 1H), 2.94--2.87 (m, 1H), 2.81 (m, 3H), 2.79--2.76 (t, *J* = 6.4, 1H), 2.68--2.64 (t, *J* = 6.0, 1H), 1.36, 1.35, 1.30 (bs, 12H), 1.23--1.21, 1.22--1.20, 1.17--1.16 (d, *J* = 6.8, 12H), 1.08--1.06 (d, *J* = 6.8, 3H), 1.05--1.03 (dd, *J*~1~ = 1.6, *J*~2~ = 6.4, 3H) ppm. ^13^C NMR (100 MHz, acetone-*d*~6~): δ, 181.8, 159.6, 145.9, 144.1, 144.0, 139.9, 138.7, 136.6, 136.5, 131.0, 130.9, 129.0, 128.9, 128.6, 127.6, 123.32, 123.28, 119.0, 114.0, 87.2, 86.7, 86.1, 86.0, 75.0, 74.9, 74.5, 74.3, 64.5, 59.6, 59.4, 55.5, 48.4, 44.1, 44.0, 40.4, 39.0, 25.0, 24.9, 24.8, 22.9, 22.5, 22.0, 21.7, 21.4, 20.8 ppm. ^31^P NMR (162 MHz, acetone-*d*~6~): δ, 149.9, 149.7 ppm.

### 7-Phenyl-1*H*-imidazo\[4,5-*c*\]pyridin-4-amine, Trifluoroacetic Acid Salt (**15a**, **3a**\*TFA) {#sec4.6.19}

This compound was synthesized in a similar fashion to **15i**. A solution of **14a** (2.09 g, 3.65 mmol) in TFA (20 mL) was placed in a 100 mL pressure tube, anisole (2.4 mL, 6 equiv) was added, and the mixture was heated at 70 °C for 24 h with vigorous stirring. It was cooled and concentrated under reduced pressure. The residue was coevaporated with toluene (3 × 25 mL) to obtain a gray-brown powder. It was taken in toluene (10 mL) and filtered, washed with toluene (2 × 5 mL) and hexanes (2 × 5 mL), and dried in air to obtain **15a** as a free-flowing, light gray powder, 1.13 g (quantitative). MS (ESI): *m*/*z*, 211.3 for \[M + H\]^+^. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ, 8.60 (bs, 2H), 8.52 (s, 1H), 7.82 (s, 1H), 7.70--7.69 (m, 2H), 7.56--7.53 (m, 2H), 7.49--7.46 (m, 1H) ppm. ^13^C NMR (100 MHz, DMSO-*d*~6~): δ, 159.4, 159.0, 158.7, 158.3, 147.5, 144.3, 132.7, 129.1, 128.5, 128.0, 126.7, 115.2 ppm.

### 3,3,4,4-Tetramethyl-1-(7-phenyl-1*H*-imidazo\[4,5-*c*\]pyridin-4-yl)pyrrolidine-2,5-dione (**16a**) {#sec4.6.20}

This compound was synthesized in a similar fashion to **16i**. A solution of **15a** (0.34 g, 1 mmol) in pyridine (10 mL) was placed in a 100 mL Schlenk flask. Tetramethylsuccinic anhydride (M~4~SA) (0.546 g, 3.5 mmol) and DBU (1.05 mL, 7 mmol) were added, and the mixture was heated at 120 °C under argon for 20 h with vigorous stirring. It was cooled and concentrated under reduced pressure. The residue was coevaporated with toluene (3 × 25 mL). The product was purified by column chromatography on silica gel eluting with 0--5% MeOH in CH~2~Cl~2~ to give a colorless syrup. It was taken in SOCl~2~ (12 mL), heated at 80 °C for 2 h, cooled, and concentrated under reduced pressure. The residue was coevaporated with EtOAc (3 × 25 mL). The product was purified by column chromatography on silica gel eluting with 0--5% MeOH in CH~2~Cl~2~ to give **16a** as a light brown foam in 92% yield (0.56 g). HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~20~H~21~N~4~O~2~: 349.16647; found: 349.16505. ^1^H NMR (400 MHz, CD~3~OD): δ, 8.75 (s, 1H), 8.52 (s, 1H), 7.76--7.75 (m, 2H), 7.61--7.51 (m, 3H), 1.40 (bs, 12H) ppm. ^13^C NMR (100 MHz, CD~3~OD): δ, 182.5, 147.9, 142.4, 139.6, 135.4, 134.4, 134.3, 130.5, 129.8, 127.0, 49.1, 21.8 ppm.

### ((2*R*,3*S*,5*R*)-3-((4-Methylbenzoyl)oxy)-5-(7-phenyl-4-(3,3,4,4-tetramethyl-2,5-dioxopyrrolid-in-1-yl)-1*H*-imidazo\[4,5-*c*\]pyridin-1-yl)tetrahydrofuran-2-yl)methyl 4-Methylbenzoate (**17a**) {#sec4.6.21}

This compound was synthesized in a similar fashion to **17i**. To a solution of **16a** (0.51 g, 1.46 mmol) in dry CH~3~CN (60 mL) in a 100 mL round-bottom flask, 60% NaH in oil (117 mg, 2.93 mmol) was added, and the mixture was vigorously stirred at room temperature under argon for 45 min. 1-(α)-Chloro-3,5-di-O-(*p*-toluoyl)-2-deoxy-[d]{.smallcaps}-ribose (0.368 g, 0.94 mmol) was subsequently added portionwise over 1 h, and the stirring was continued at room temperature for overall 5 h. The mixture was filtered through Celite and concentrated. The product was purified by column chromatography on silica gel eluting with 0--50% EtOAc in hexanes. Compound **17a** was obtained as a yellowish syrup in 64% yield (0.64 g). HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~41~H~40~N~4~O~7~: 701.29757; found: 701.29626. ^1^H NMR (400 MHz, CDCl~3~): δ, 8.33 (s, 1H), 8.31 (s, 1H), 7.86--7.84 (d, *J* = 8.0, 2H), 7.75--7.73 (d, *J* = 8.0, 2H), 7.46 (bs, 4H), 7.32--7.28 (m, 1H), 7.31--7.29 (d, *J* = 8.0, 2H), 7.24--7.22 (d, *J* = 8.0, 2H), 5.96--5.93 (dd, *J*~1~ = 5.2, *J*~2~ = 8.8, 1H), 5.46--5.44 (m, 1H), 4.62--4.53 (m, 2H), 4.38--4.36 (m, 1H), 2.48 (s, 3H), 2.40 (s, 3H), 2.30--2.16 (m, 2H), 1.40 (bs, 12H) ppm. ^13^C NMR (100 MHz, CDCl~3~): δ, 181.7 (Cq), 166.2 (Cq), 165.6 (Cq), 144.7 (Cq), 144.5 (Cq), 142.9, 142.7, 138.4 (Cq), 138.0 (Cq), 137.4 (Cq), 134.8 (Cq), 130.0, 129.7, 129.6, 129.3, 129.0, 128.8, 126.6 (Cq), 126.4 (Cq), 123.5 (Cq), 85.9, 82.8, 74.9, 64.2 (CH~2~), 48.1 (Cq), 40.1 (CH~2~), 21.9, 21.8, 21.6 ppm. For the critical NOESY correlations, see [Figure S4](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01159/suppl_file/ao7b01159_si_001.pdf) and copies of spectra ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01159/suppl_file/ao7b01159_si_001.pdf)).

### 1-(1-((2*R*,4*S*,5*R*)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7-phenyl-1*H*-imidazo\[4,5-*c*\]pyridin-4-yl)-3,3,4,4-tetramethylpyrrolidine-2,5-dione (**18a**) {#sec4.6.22}

This compound was synthesized in a similar fashion to **18i**. To a solution of **17a** (0.44 g, 0.63 mmol) in dry MeOH (6 mL) in a 25 mL round-bottom flask, NaOMe (102 mg, 1.89 mmol) was added, and the mixture was stirred at room temperature under argon for 2 h. It was concentrated in vacuo, and the product was purified by column chromatography on silica gel eluting with 0--10% MeOH in CH~2~Cl~2~ to obtain **18a** as a white foam in 58% yield (0.17 g). HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~25~H~29~N~4~O~5~: 465.21383; found: 465.21228. ^1^H NMR (400 MHz, CD~3~OD): δ, 8.85 (s, 1H), 8.19 (s, 1H), 7.56 (m, 5H), 5.97--5.94 (t, *J* = 6.0, 1H), 4.37--4.33 (m, 1H), 3.78--3.65 (m, 3H), 2.35--2.28 (m, 1H), 1.96--1.90 (ddd, *J*~1~ = 4.4, *J*~2~ = 6.0, *J*~3~ = 10.8, 1H), 1.39 (bs, 12H) ppm. ^13^C NMR (100 MHz, CD~3~OD): δ, 183.4 (Cq), 146.5 (Cq), 143.1, 139.4 (Cq), 138.7 (Cq), 138.6 (Cq), 135.6 (Cq), 130.9, 130.2, 129.9, 126.0 (Cq), 88.9, 87.1, 71.2, 62.3 (CH~2~), 49.0 (Cq), 42.9 (CH~2~), 21.9, 21.8 ppm.

The attempted tritylation of **18a** was carried forward in a similar fashion to **18i**. To a solution of **18a** (0.15 g, 0.323 mmol) in pyridine (3 mL) under Ar, 4,4′-dimethoxytrityl chloride (DMT-Cl) (0.153 g, 0.453 mmol) was added in one portion, and the mixture was stirred at room temperature for 4.5 h. TLC analysis indicated that some starting material remained and then additional DMT-Cl was added (0.076 g, 0.225 mmol). After 3.5 h, the starting material still remained and then triethylamine (45 μL, 0.323 mmol), cat. DMAP (10 mg), and additional DMT-Cl (44 mg, 0.129 mmol) were added. After 8 h, most of the starting material was consumed, the mixture was concentrated in vacuo, and the residue was coevaporated with toluene (3 × 10 mL) to remove residual pyridine. A TLC analysis indicated that an extensive deglycosylation occurred, indicating the instability of the compound, which may be ascribed to the electronic character of phenyl group at the position 3, as suggested by other reports.^[@ref15]^ Deglycosylation was also observed to occur upon mild heating of the TLC plate to remove pyridine before analysis.

Synthesis of 3-Deazahypoxanthine **21c** {#sec4.7}
----------------------------------------

### 7-Phenethyl-1*H*-imidazo\[4,5-*c*\]pyridin-4-amine, Trifluoroacetic Acid Salt (**15c**) {#sec4.7.1}

This compound was synthesized in a similar fashion to **15i**. A solution of **14c** (0.327 g, 0.55 mmol) in TFA (8 mL) was placed in a 100 mL pressure tube, anisole (0.36 mL, 6 equiv) was added, and the mixture was heated at 70 °C for 21 h with vigorous stirring. It was cooled and concentrated under reduced pressure. The residue was coevaporated with toluene (3 × 15 mL) to obtain **15c** (ca. 0.2 g, quantitative) as a syrup that was taken into next step without further purification.

### 7-Phenethyl-1,5-dihydro-4*H*-imidazo\[4,5-*c*\]pyridin-4-one (**21c**) {#sec4.7.2}

This compound was synthesized according to the general procedure.^[@ref56]^ To a solution of crude **15c** (ca. 0.2 g, 0.55 mmol) in acetone/H~2~O/AcOH (4/2/2 mL) was added NaNO~2~ in one portion (0.755 g, 10.9 mmol) and stirred at room temperature for 5 h in a closed vessel. The pressure was carefully released, and the mixture was carefully neutralized with aq NaHCO~3~ and diluted with Et~2~O (50 mL). The phases were shaken, and the precipitated solid was filtered, washed with water and Et~2~O, and dried in air to obtain **21c** as a light yellow solid (75 mg, 57% based on **14c**). HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~14~H~14~N~3~O: 240.11369; found: 240.11281. MS (ESI): *m*/*z*, 240.3 for \[M + H\]^+^, 262.2 for \[M + Na\]^+^, 501.2 for \[2M + Na\]^+^; 238.3 for \[M -- H\]^−^. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ, 10.9 (bs, 1H), 8.09 (s, 1H), 7.26--7.16 (m, 5H), 6.79 (s, 1H), 2.93--2.89 (m, 4H) ppm. ^13^C NMR (100 MHz, DMSO-*d*~6~): δ, 156.1, 141.6, 141.2, 128.4, 128.2, 125.8, 124.9, 110.7, 35.1, 29.7 ppm.

### Purification of Salts **15** {#sec4.7.3}

TFA salts **15** were used for synthetic purposes typically without further purification. Pure amines could be also isolated as water-soluble HCl salts as exemplified below. Free amines could be obtained by neutralization of their aqueous solutions with Na~2~CO~3~, followed by extraction with AcOEt.

### 7-Phenethyl-1*H*-imidazo\[4,5-*c*\]pyridin-4-amine, Hydrochloric Acid Salt (**15c**\*HCl) {#sec4.7.4}

A solution of **14c** (0.173 g, 0.29 mmol) in EtOH/H~2~O/HCl conc. (8/8/4 mL) was heated under reflux condenser at 100 °C for 23 h. It was cooled, and EtOH was removed under reduced pressure. It was diluted with aq HCl and washed with Et~2~O (40 mL, discarded) to remove a precipitated oil. The residue was concentrated and dried under vacuum to obtain **15c\*HCl** (ca. 0.08 g, quantitative) as an off-white solid. HRMS (ESI): *m*/*z* \[M + H\]^+^ calcd for C~14~H~15~N~4~: 239.12968; found: 239.12930. MS (ESI): *m*/*z*, 239.3 for \[M + H\]^+^; 237.3 for \[M -- H\]^−^, 273.0 for \[M + Cl\]^−^. ^1^H NMR (400 MHz, D~2~O): δ, 8.35 (s, 1H), 7.28--7.19 (m, 4H), 7.11--7.09 (m, 2H), 3.09--3.05 (m, 2H), 2.99--2.96 (m, 2H) ppm. ^13^C NMR (100 MHz, D~2~O): δ, 146.6, 143.6, 140.6, 128.8, 128.6, 127.0, 126.5, 123.8, 114.7, 34.6, 29.3 ppm.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.7b01159](http://pubs.acs.org/doi/abs/10.1021/acsomega.7b01159).Detailed experimental procedures and characterization data of all synthesized compounds; copies of ^1^H and ^13^C NMR spectra ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01159/suppl_file/ao7b01159_si_001.pdf))

Supplementary Material
======================

###### 

ao7b01159_si_001.pdf

The authors declare no competing financial interest.

This research was supported by Michigan Technological University (MTU, REF-SEED and Portage Health Foundation, M.T. Grant \#2015-025). The authors gratefully acknowledge MTU Chemical Advanced Resolution Methods (ChARM) Laboratory for HRMS analysis and Jerry Lutz for help with 2D-NMR experiments.
